

Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.5662/wjm.v5.i3.164 World J Methodol 2015 September 26; 5(3): 164-174 ISSN 2222-0682 (online) © 2015 Baishideng Publishing Group Inc. All rights reserved.

SYSTEMATIC REVIEWS

Prevalence of antibiotic resistance in *Helicobacter pylori*: A recent literature review

Reza Ghotaslou, Hamed Ebrahimzadeh Leylabadlo, Yalda Mohammadzadeh Asl

Reza Ghotaslou, Research Center of Infectious and Tropical Diseases, Tabriz University of Medical Sciences, Tabriz 51663-39888, Iran

Reza Ghotaslou, Hamed Ebrahimzadeh Leylabadlo, Yalda Mohammadzadeh Asl, Department of Microbiology, School of Medicine, Tabriz University of Medical Sciences, Tabriz 51666-14766, Iran

Author contributions: Ghotaslou R conceptualized, designed the review and carried out the analysis; Ebrahimzadeh Leylabadlo H and Mohammadzadeh Asl Y contributed equally to the work; all authors reviewed and approved the final manuscript as submitted.

Conflict-of-interest statement: No conflict of interest exists.

Data sharing statement: No additional data are available.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/ licenses/by-nc/4.0/

Correspondence to: Reza Ghotaslou, MD, PhD, Associated Professor of Medical Microbiology, Department of Microbiology, School of Medicine, Tabriz University of Medical Sciences, Tabriz 51666-14766, Iran. rzgottaslo@yahoo.com Telephone: +98-41-33364661 Fax: +98-41-33364661

Received: May 13, 2015 Peer-review started: May 20, 2015 First decision: June 24, 2015 Revised: July 29, 2015 Accepted: August 20, 2015 Article in press: August 21, 2015 Published online: September 26, 2015

Abstract

AIM: To review previous studies (the last 6 years) about the *Helicobacter pylori* (*H. pylori*) antibiotic resistance in order to evaluate the trend in antibiotic resistance.

METHODS: In this study, the PubMed, MEDLINE, Science Direct, Google Scholar and Scielo manuscripts were reviewed from 2009 to 2014.

RESULTS: On the whole rates of *H. pylori* antibiotic resistance were 47.22% (30.5%-75.02%) for metronidazole, 19.74% (5.46%-30.8%) for clarithromycin, 18.94% (14.19%-25.28%) for levofloxacin, and 14.67% (2%-40.87%) for amoxicillin, 11.70% (0%-50%) for tetracycline, 11.5% (0%-23%) for furazolidon and 6.75% (1%-12.45%) for rifabutin. The frequency of tetracycline, metronidazole and amoxicillin resistance was higher in Africa, while clarithromycin and levofloxacin resistance was higher in North America and Asian, respectively.

CONCLUSION: The most sensitive drug is rifabutin and the lowest sensitive drug is metronidazole in the world. The worldwide *H. pylori* antibiotic resistance to clarithromycin and levofloxacin has increased during the last 6 years. The present systematic review show alarming results and a novel plan is needed for eradication therapy of *H. pylori* infections.

Key words: Antibiotic resistance; *Helicobacter pylori*; Worldwide

© **The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Because of the rising frequency of antimicrobial resistance, management of *Helicobacter pylori* (*H. pylori*) infections is a challenge for physicians. We found global frequency rate of resistance is high in Africa. The



WJM | www.wjgnet.com

most sensitive drug is rifabutin and the lowest sensitive drug is metronidazole in the world. The worldwide *H. pylori* antibiotic resistance to clarithromycin and levofloxacin has increased during the last 6 years. Resistances to antimicrobial agent's reports describe dramatic decrease of antibiotics efficacy.

Ghotaslou R, Ebrahimzadeh Leylabadlo H, Mohammadzadeh Asl Y. Prevalence of antibiotic resistance in *Helicobacter pylori*: A recent literature review. *World J Methodol* 2015; 5(3): 164-174 Available from: URL: http://www.wjgnet.com/2222-0682/full/ v5/i3/164.htm DOI: http://dx.doi.org/10.5662/wjm.v5.i3.164

INTRODUCTION

Helicobacter pylori (H. pylori) is a motile, curved and Gram negative bacillus^[1]. *H. pylori* certainly is the most prevalent human infection, the frequency of infection due to *H. pylori* is nearly 50% in the world and in developing country is as high as 80%-90%^[2]. This bacterium colonizes the stomach of human and its infection is correlated with gastritis, peptic ulcer disease and extra-digestive diseases^[3,4]. *H. pylori* is also considered as a human carcinogen^[5]. Since, *H. pylori* eradication therapy represents a key clinical essential. Unfortunately, therapy against *H. pylori* has turned out to be more difficult over the years, principally due to the great decrease of standard eradication therapies efficacy.

Although H. pylori is sensitive to many antibiotics in vitro, just a few antibiotics can be used in vivo to treat infected patients. Management of H. pylori infections are recommended in all suggestive individuals^[6]. According to the latest Maastricht Guidelines, in regions of low clarithromycin resistance, clarithromycincontaining treatments are recommended for first-line empirical treatment^[7]. In regions of high resistance to clarithromycin, the quadruple treatment including bismuth has been proposed as first-line treatment. In case of unavailability of this therapy, non-bismuth (three antibiotics plus Proton pump inhibitors) quadruple therapy and the so-called "sequential therapy" (that includes five days of PPIs plus amoxicillin followed by five more days of PPIs plus metronidazole and clarithromycin) have been recommended as an alternative^[7]. Table 1 is shown mode of actions and resistance mechanisms of antibiotics used for treatment of H. pylori infection.

Failure of treatment in *H. pylori* infections has become an actual subject for physicians. The cause of treatment failure is many that can be grouped into microorganismrelated factors, host-related factors and treatmentrelated factors. *H. pylori* resistance to antibiotic is widely recognized as the chief reason for treatment failure^[1,8]. Furthermore, antibiotic resistance should be considered as a lively idea, since its prevalence can change not only among diverse countries, but also between two different periods in the same area^[1,9-11]. The rate of antibiotic resistance in H. pylori has been evaluated worldwide. However, most researches originated from single center, included only a small number of bacteria, were often restricted to selected patients, and used different techniques to evaluate antibiotic susceptibility. Though, the investigation platform is luxurious; and only performed in few countries as: United Kingdom, German, Finland^[12-18]. Antibiotic use for infections other than H. pylori is accounting for the extensive raise antibiotic resistance rate in *H. pylori*^[19]. Because of the value of *H. pylori* therapy, antimicrobial susceptibility testing has been widely done. Since, H. pylori antibiotic resistance is fast growing worldwide, an eradication policy based on pre-treatment susceptibility testing is going to get more attractive than in the past $^{[1,7]}$.

The objective of this paper was to review previous studies about the rates of antimicrobial resistance in *H. pylori* isolates obtained from worldwide during last 6 years in order to evaluate the trend of antibiotic resistance.

MATERIALS AND METHODS

In the present study, different computer-assisted searches were achieved using PubMed, MEDLINE, Science Direct, Google Scholar and Scielo. Separately searches were carried out on all English language literatures published through 2009 to 2014, by the key words: Helicobacter pylori, H. pylori, resistance, metronidazole, levofloxacin, amoxicillin, clarithromycin, tetracycline, and rifabutin. Full articles related searches were saved, and articles written in foreign languages were translated when essential. When more than one publication from the same author was obtainable, only new version, counting the whole population was enrolled. Two investigators (Ebrahimzadeh Leylabadlo H and Mohammadzadeh Asl Y) independently and in a blinded manner assessed the articles using predesigned data extraction.

The following information was collected: (1) sum of bacteria incorporated; (2) rate of antibiotic resistant; and (3) the geographic area involved. The data were summarized in extraction table and analyzed manually. Finally, Excel 2007 software was used to draw charts.

RESULTS

During 6 years a total of 52008 *H. pylori* isolates meeting the inclusion criteria were identified. Eighty-seven studies from 2009 to 2014 on *H. pylori* antimicrobial resistance in the different countries were included; there were 43 Asian^[20-62], 10 American^[63-72], 5 African^[73-77], and 29 European studies^[78-106]. On the whole rates of *H. pylori* antibiotic resistance were 47.22% (30.5%-75.02%) for metronidazole, 19.74% (5.46%-30.8%) for clarithromycin, 18.94% (14.19%-25.28%) for levofloxacin, and 14.67% (2%-40.87%) for amoxicillin, 11.70% (0%-50%) for tetracycline, 11.5% (0%-23%) for

Table 1 Mode of action, resistance mechanisms of antimicrobial agents used for treatment of *Helicobacter pylori* infection

Antibiotic	Mode of action	Resistance mechanisms
Metronidazole	Electron reduction processes, leads to the formation of nitro- anion radicals and subsequent DNA damage	(1) Poor drug uptake and/or increased drug efflux; (2) enhanced activity of DNA repair enzymes; (3) increased oxygen scavenging abilities; and (4) decreased antibiotic activation arising from changes in metronidazole-reducing enzymes ^[16]
Clarithromycin	The inhibition of protein synthesis by binding and slowing down the activity of the bacterial ribosomal unit ^[17]	rRNA-point mutations
Amoxicillin	The inhibition cell wall synthesis	<i>pbp</i> gene mutations, membrane permeability alterations and efflux pumps ^[17]
Tetracycline	Reversible inhibition protein synthesis	Three contiguous nucleotides mutation in the 16S rRNA gene ^[17]
Fluoroquinolones	Inhibiting DNA gyrase, type II topoisomerase, and topoisomerase IV ^[17]	Point mutations in the quinolones resistance determining regions
Rifabutin	Inhibits the b-subunit of <i>H. pylori</i> DNA-dependent RNA polymerase encoded by the <i>rpo</i> B gene ^[18]	Mutation of the <i>rpoB</i> gene ^[18]

H. pylori: Helicobacter pylori.

Table 2 Antibiotic resistance rates in different continental areas										
Region (n)	Cla	Amo	Met	Tet	Lev	Rif	Fur			
	%	%	%	%	%	%	%			
Asia (23748)	27.46	23.61	46.57	7.38	25.28	12.45	23			
South America (587)	12.88	6.56	52.85	0	21.23	NR	0			
North America (818)	30.8	2	30.5	0	19	NR	NR			
Europe (26024)	22.11	0.35	31.19	1.15	14.19	1	NR			
Africa (831)	5.46	40.87	75.02	50	15	NR	NR			
Total (52008)	19.74	14.67	47.22	11.70	18.94	6.75	11.5			

Amo: Amoxicillin; Cla: Clarithromycin; Met: Metronidazole; Tet: Tetracycline; Lev: Levofloxacin; Rif: Rifabutin; Fur: Furazolidon; *n*: Number; NR: Not reported.




Figure 1 Antibiotic resistance rates to 4 most common used antibiotics in different continental areas.

furazolidon and 6.75% (1%-12.45%) for rifabutin. The frequency of resistance to antibiotics in various continents and countries are demonstrated in Tables 2 and 3, Figures 1 and 2.

DISCUSSION

Monitoring of resistance to antimicrobial agents is important for *H. pylori* infections therapy in medical

practice^[17]. Resistance to antimicrobial agents creates at risk *H. pylori* eradication in the world^[10,98]. The most recent recommendations on *H. pylori* therapy suggested that initially management had better be personalized based on clarithromycin and metronidazole resistance. In fact, fourteen days triple-therapy is recommended in area where resistance to clarithromycin is more than 15% to 20%, if resistance to metronidazole is more than 40%, the association with amoxicillin is

2014 95 3.7.	2014 96 307 5.7 5.7 5.7 5.7 DDM 2013 78 15.3 6.4 5.1 DDM 2012 112 14.3 2.66 7.68 18.7 2.66 DDM 2011 17 45.2 2.94 6.5 37.1 6.4 DDM 2010 12 5 2.94 4.8 3 DDM 2010 12 5 0.4 6.8 7.34 9 Erest 2014 7.73 82.8 0 2.8 2.16 0 1.7 2014 7.73 82.8 0 2.13			Isolates	Cla	Amo	Met	Tet	Lev	Rif	Fur	Method	Ref
nm2033221398646464939395<	ana2033219844000 <td></td> <td>2014</td> <td>(N)</td> <td>(%)</td> <td>(%)</td> <td>(%)</td> <td>(%)</td> <td>(%)</td> <td>(%)</td> <td>(%)</td> <td>E Test</td> <td>[20]</td>		2014	(N)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	E Test	[20]
any any any 2012306451515657.156.657.4	ana20.37.80.36.45.17.4					0.0	(1.1	0					[20]
nn202100941076.95.3	nn20215094100760935.35.41.01.0201212114.322.96.537.126.60.01.01.02010121520413.43.401.01.01.02010121520413.43.401.71.61.02010212306.87.47.43.401.71.61.0201021321.51.06.101.76.81.01.01.0101327.38.400.101.56.81.01.01.01.020103.78.401.17.68.10.01.61.0 <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td>0</td><td></td><td></td><td></td><td></td><td>[21]</td></td<>							0					[21]
201211214.326.676.816.726.676.176.4DDM201014.224.32.440.54.8-61.4DDM201013.2306.874.49201013.2306.874.47.0201017.38.9016.6013.76.8201037.487.20.36.39.120.3201037.487.20.36.30.12.0201037.487.20.30.30.1201037.487.20.30.22.0	201211214.326.965.537.126.60002010125.04.434.04.34.001.02010132306.87.491.20.11.0201317.3121.50.19.420.60.10.01.0201037.437.20.36.83.3.39.420.60.10.01.0201037.437.20.36.30.11.0												[22]
111 <th< td=""><td>2011 97 452 249 65. 7.7 </td><td>an</td><td></td><td></td><td></td><td></td><td></td><td></td><td>5.3</td><td></td><td></td><td></td><td>[23</td></th<>	2011 97 452 249 65. 7.7	an							5.3				[23
201012132414.32.44.8	201042432.44.34.34.5ErestI20101.32306.87.49ErestI20131.7312.150.10.6.40.26.40.1ADMI201037.437.20.36.160.12.76.80.8K201037.437.20.36.160.11.76.80.8KK200037.437.20.36.30.11.76.8KKK20111.252.90.30.31.1KKKKKK20141.033.1.140.2KK <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>28.6</td><td></td><td></td><td>[24]</td></td<>									28.6			[24]
200121320443	200121320443				45.2	23.9	65.5				61.4		[25]
1011021031041041041041041041041041041041031712150.16.40.60.60.1NCNC1033743720.36.31.250.36.8NCNC1041246.333.39.401.67NCNC1071111322.90.71.7NCNCNC1041246.60.70.7NCNCNC1041322.90.70.7NCNCNC1011310.48.60.70.7NCNC1011310.61.60.70.41.5NC1011350.80.70.70.70.7NC1011350.80.70.70.70.7NC1011351.87.90.70.7NCNC1011371.87.90.70.7NCNC1011371.87.90.70.7NCNC1011371.87.90.70.7NCNC1011381.71.81.8NCNC1011371.81.71.8NCNC1011371.91.91.7NCNC1011371.91.91.9NCNC <td>20101.22306.87.49For all or a</td> <td></td> <td>2011</td> <td>42</td> <td></td> <td>2.4</td> <td>40.5</td> <td>4.8</td> <td></td> <td></td> <td></td> <td></td> <td>[26]</td>	20101.22306.87.49For all or a		2011	42		2.4	40.5	4.8					[26]
1047748080.080912.012.3E.T.et10177384.90.06.60.010.76.8PCR1007384.90.06.60.010.710.710.7100368.333.39.40.15.3FT-et10113325.90.02.1FT-etFT-et10110335.6FT-etADM10113355.6FTADM10115015.210.02.15ADM10115015.210.02.15ADM10115015.210.02.15ADM10115012.236.30.02.15ADM1014161127.5014.4E-Test1014161127.5014.4E-Test1014161127.5014.4E-Test1014161127.5014.4E-Test101416210.07.5014.4E-Test101416212.37.94.3E-TestADM101416212.310.07.5014.4E-Test101416312.015.510.015.4ADM101416312.015.510.015.4ADM101416312.015.515.4ADM1014164 <td>20147380808012.312.45.47.</td> <td></td> <td>2010</td> <td>121</td> <td>5</td> <td></td> <td>44</td> <td>3</td> <td></td> <td></td> <td></td> <td>E-Test</td> <td>[27]</td>	20147380808012.312.45.47.		2010	121	5		44	3				E-Test	[27]
bina20397332150.109542060.1376.580.158bina009749720.30830.125.36.58FT-852040.320.320.400.1670.00120412336202.120412336202.120412331.140.2201320486.496.8201416331.140.2201320486.496.820141651.52.4590.45 <t< td=""><td>bina20131731173413074001400140014001400140014000<!--</td--><td></td><td>2010</td><td>132</td><td>30</td><td>6.8</td><td>73.4</td><td>9</td><td></td><td></td><td></td><td>E-Test</td><td>[28]</td></td></t<>	bina20131731173413074001400140014001400140014000 </td <td></td> <td>2010</td> <td>132</td> <td>30</td> <td>6.8</td> <td>73.4</td> <td>9</td> <td></td> <td></td> <td></td> <td>E-Test</td> <td>[28]</td>		2010	132	30	6.8	73.4	9				E-Test	[28]
JahaJuli7384.90.06.601.76.8PCR200368.333.39.40.353.31.40.11.67DDM2044.3225.920.71.40.11.67DDM1.67DDM201310733.14.020.75.7ADMDDM201410733.14.02.75.7ADM201310648.60.11.8PCRADM20141.615.67.84.5ADM20141.628.59.48.60.12.55ADM20141.611.28.60.12.55ADMADM20141.611.28.60.12.55ADMADM20141.621.28.60.12.55ADMADM20141.621.28.60.12.55ADMADM20141.621.28.60.12.5ADMADM20141.611.28.60.11.6ADM20141.621.61.61.61.6ADMADM20141.621.61.61.61.6ADMADM20141.611.21.61.61.6ADMADM20141.611.21.61.61.61.61.61.620141.611.21.61.6 <td< td=""><td>hina20107384.90.061.601.376.8PCR2009368333.394.4016.7DDM201413525.90.7F.Test201413525.90.72013201486.48.271.3201313325.62014121.285936.302014121.28500.0520141661.220141611.2<</td><td></td><td>2014</td><td>73</td><td>80.8</td><td>0</td><td>58.9</td><td></td><td>12.3</td><td></td><td></td><td>E-Test</td><td>[29]</td></td<>	hina20107384.90.061.601.376.8PCR2009368333.394.4016.7DDM201413525.90.7F.Test201413525.90.72013201486.48.271.3201313325.62014121.285936.302014121.28500.0520141661.220141611.2<		2014	73	80.8	0	58.9		12.3			E-Test	[29]
JahaM1738490.06.601.76.8PCR200548.30.39.40.350.31.62DDMapan1348.60.02.11.62DDM201413525.920.7F.T201413535.6ADM201313355.6ADM20141228.59.48.30.120141238.5ADM20131508.630.120141218.5ADM201315020141611236.30.120141621236.40.11.420141611236.40.11.420141621.120141641.220141641.2 <td>Jaha 20107.38.49.06.601.76.5PCR20093.68.33.39.4.401.6.7DDM20411.352.50.70.71.6.7DDM20141.352.50.70.7NNDM20141.373.6.10.71.7NDM20111.535.67.7NDMNDM20141.621.4.8NNDMNDM20131.561.52.459.00.2ADM20141.611.23.6.0NNDMNDM20131.551.51.50.11.4.4ETest20141.611.23.6.01.4.4ETestNDM20119.007.501.4.4ETest20119.007.501.4.4ETest20119.01.78.37.94.3NNDM20119.01.78.37.94.3NNDM20141.644.7.88.37.94.3NNDM20149.82.1.51.7NNDMNDM20149.81.79.11.4ETestNDM20149.82.53.81.7NDMNDM20149.82.59.81.81.8.8NDM20149.82.58.85.81.8.81.8.8<!--</td--><td></td><td>2013</td><td>17731</td><td>21.5</td><td>0.1</td><td>95.4</td><td></td><td>20.6</td><td></td><td>0.1</td><td>ADM</td><td>[30]</td></td>	Jaha 20107.38.49.06.601.76.5PCR20093.68.33.39.4.401.6.7DDM20411.352.50.70.71.6.7DDM20141.352.50.70.7NNDM20141.373.6.10.71.7NDM20111.535.67.7NDMNDM20141.621.4.8NNDMNDM20131.561.52.459.00.2ADM20141.611.23.6.0NNDMNDM20131.551.51.50.11.4.4ETest20141.611.23.6.01.4.4ETestNDM20119.007.501.4.4ETest20119.007.501.4.4ETest20119.01.78.37.94.3NNDM20119.01.78.37.94.3NNDM20141.644.7.88.37.94.3NNDM20149.82.1.51.7NNDMNDM20149.81.79.11.4ETestNDM20149.82.53.81.7NDMNDM20149.82.59.81.81.8.8NDM20149.82.58.85.81.8.81.8.8 </td <td></td> <td>2013</td> <td>17731</td> <td>21.5</td> <td>0.1</td> <td>95.4</td> <td></td> <td>20.6</td> <td></td> <td>0.1</td> <td>ADM</td> <td>[30]</td>		2013	17731	21.5	0.1	95.4		20.6		0.1	ADM	[30]
2005748720.38391.2503F.T.S.I2041248620.02.1016.6DOM2041352.50.22.10.016.7DOM2014107531.10.27.77.7ADM20140.135.57.3570.0DOM201110335.57.30.024.5ADM201216.510.87.024.55ADM201316.51.152.450.024.55ADM201416.110.87.70.01.4E.T.S.I201416.110.87.70.01.4E.T.S.I201416.110.87.70.01.4E.T.S.I201416.27.80.07.50.11.4E.T.S.I201417.86.87.78.71.4E.T.S.I201417.86.87.78.71.4E.T.S.I201417.87.87.94.32.1E.T.S.I201417.87.87.94.32.1E.T.S.I201417.87.87.97.47.5DDM201417.87.87.97.47.5DDM201417.87.87.97.47.5DDM201417.87.97.47.57.57.5F.T.S.I201418.90.0 <t< td=""><td>and and<b< td=""><td>hina</td><td>2011</td><td>73</td><td>84.9</td><td>0</td><td>61.6</td><td>0</td><td>13.7</td><td>6.8</td><td></td><td>PCR</td><td>[31]</td></b<></td></t<>	and <b< td=""><td>hina</td><td>2011</td><td>73</td><td>84.9</td><td>0</td><td>61.6</td><td>0</td><td>13.7</td><td>6.8</td><td></td><td>PCR</td><td>[31]</td></b<>	hina	2011	73	84.9	0	61.6	0	13.7	6.8		PCR	[31]
apan2009368.38.39.49.01.6.7DDMapan201413525.90.7ADM201413731.10.2-0.2-ADM20131378.6-0.2-ADM201115335.6ADM20141228.5936.30-ADM20141251552.450.30.5-ADM20141651.52.450.30.5-ADM20131501.61.20.30.520141611.20.30.520141010.60.30.701.4-20141010.70.37.501.4-20141026.80.77.94.120141026.80.77.91.420191772.11.97.91.920141.61.20.94.21.920141.61.30.94.21.820141.61.30.94.51.820141.11.30.92.520141.11.3<	appan30430394.401.6.7DDM20413525.90.7ADM20413731.00.731.0201320464.48.271.35720141218.599.6.3020142128.599.6.30 <t< td=""><td></td><td>2010</td><td>374</td><td>37.2</td><td>0.3</td><td>63.9</td><td>1.2</td><td>50.3</td><td></td><td></td><td>E-Test</td><td>[32]</td></t<>		2010	374	37.2	0.3	63.9	1.2	50.3			E-Test	[32]
apan201413525207Image: state	apan2014135259207E.T.et2014107331.10.02ADM201320486.48.271.357ADM20106136.1014.8PCR20106136.1014.8PCR20106136.1014.8PCR20106136.1014.8PCR20106136.1014.8PCR20131051.52.459030.5ADM20131051.52.459030.5PCR20131061.236.6PCRPCR20141026.802.306.8020111872.1037.5014.4PCR2010972.1PCRPCRPCRPCR20111872.104.518.2PCRPCR20144647.85.37.91.3PCRPCR2014982.53.911.7PCRPCRPCR2014462.1304.269.13.3PDM2014982.51.6PCRPCRPCR2014462.1304.269.13.3PDM2014682.151.6PCRPCRPCR2014682.15PCRPCRPCR2014										16.7		[33]
apam20410733140.257I. Terist201320486.48.27.357ADM201310335.6PCRPCR201412.28.598.30ADM201412.5152.4598.30ADM2013150152.4598.30ADM20141651.52.459.30.02.45ADM20141611.28.39.301.4ETest20141610.07.501.4ETest20141620.07.501.4ETest20141672.10.07.501.4ETest20141622.10.07.501.4ETest20141672.10.07.50.01.4ETest20101752.10.07.50.01.4ETest20101760.21.51.51.51.51.520101631.61.67.69.21.5ETest20141611.51.61.69.02.5ETest20141611.51.61.69.02.5ETest20141611.61.69.02.5ETest1.620141611.61.69.05.81.61.61.6	papa2014107331.140.2IIIIDM201320486.48.271.357ADMI201015355.6PCRADMI201421285936.30ADMI201412285936.30ADMI20131551.52.4550.702.455ADMI20141611.236.6 <td></td> <td>[34]</td>												[34]
1 1014 1073 31.1 402 400 2011 133 56 PCR ADM 2010 61 36.1 0 14.8 PCR 2010 61 36.1 0 24.5 ADM 2014 122 85 9 36.3 0 ADM 2013 155 1.5 2.45 507 0 24.5 ADM 2013 165 1.5 2.2 0.3 0.5 ADM 2012 155 16.8 0 22.5 0 14.4 $E-Test$ $41daysia$ 2014 162 6.8 0 $1-Test$ $E-Test$ 2011 187 2.1 0 37.4 0 1 $E-Test$ 2011 187 2.1 0 37.5 89 12.5 $E-Test$ 2014 98 2.5		anan				0							[35]
20132013201486.48.27.135.7ADM20106136.101.8ADM20142128.59.43.602.4.5ADM2013150-6ADM2013150-6ADM20141611.23.602.4.5ADM20131601.20.30.0520141026.80.023.30.120141026.80.037.401.4-20191872.120101972.120101972.120111972.1201214918.20.037.48.91.220144.647.854.37.34.320141982.33.01.1201419812.30.02.51.8201419812.30.02.51.8201410.119.317.69.32.51.8<	2013 204 8.64 8.27 7.13 5.7 ADM 2010 133 556	ipun											[36]
201115355.6936.304.8ADM20142128.5936.30ADM20131661.52.4550.702.4.55ADM20131651.02.4.5ADMADM20131681.02.4.5ADMADM201218510.82.236.601.4ADM201410.26.803.206.80ETest201410.26.803.701.4ETest201410.72.103.701.4ETest20191872.103.791.2ADM20101872.103.791.2ADM20111973.63.78.91.2ADMADM20121783.63.78.91.2ADMADM20149.21.31.43.2ADMADM201419.11.1.93.2ADMADMADM201410.11.1.93.2ADMADMADM201410.21.2.91.3.4ADMADM201410.410.00.2.51.8.41.3.81.3.8201410.410.00.5.81.8.41.3.4ADM201410.410.00.31.4ADMADM201410.71.4 <td>201113355.6936.304.820142128.5936.30ADM2014115</td> <td></td> <td></td> <td></td> <td></td> <td>6.0</td> <td></td> <td></td> <td>57</td> <td></td> <td></td> <td></td> <td></td>	201113355.6936.304.820142128.5936.30ADM2014115					6.0			57				
20106.13.6.101.4.8ADMiouth Korea2131502.4.5024.5ADM20131506ADMADM20141611.23.6.30.5Ferest20141611.23.6.30.5Ferest20141026.6.80.02.30.01.420141026.6.80.01.4Ferest20141072.101.4Ferest20141782.101.2Ferest20141782.13.3A.3Ferest20141782.32.94.3Ferest201418204.51.8.2Ferest201418204.51.8.2Ferest20141831.02.69.13.3DDM201418204.51.8.2Ferest201418304.51.8.2Ferest20141831.602.51.8.2Ferest20141831.602.51.8.2Ferest20141831.60.99.51.8.2Ferest20141931941.60.92.51.8.2Ferest201419419.11.91.91.91.91.9201419319191.91.91.91.920141919 <t< td=""><td>20106136.101.4.8ADM20142128.59.63024.55ADM20131651.1.52.4550.7024.55ADM20131651.1.52.4550.7024.55ADM20131651.1.236.6-F-TestI20141611.236.60E-TestI20141026.802.306.80E-Test20111872.1001.4.4E-TestI201217836.57.3.94.3E-TestI20144.647.854.37.3.94.3E-TestI20142171863.7891.2IADM2014923.324.8III2014923.301.61.8.2II2014933.51.8.2IIII20149418.204.5.51.8.2II201414.93.21.93.2III201414.93.21.93.2III201414.93.21.93.2III201918.01.60.22.5III201918.01.60.23.81.8II20</td><td></td><td></td><td></td><td></td><td>8.2</td><td>/1.5</td><td></td><td>57</td><td></td><td></td><td></td><td>[37]</td></t<>	20106136.101.4.8ADM20142128.59.63024.55ADM20131651.1.52.4550.7024.55ADM20131651.1.52.4550.7024.55ADM20131651.1.236.6-F-TestI20141611.236.60E-TestI20141026.802.306.80E-Test20111872.1001.4.4E-TestI201217836.57.3.94.3E-TestI20144.647.854.37.3.94.3E-TestI20142171863.7891.2IADM2014923.324.8III2014923.301.61.8.2II2014933.51.8.2IIII20149418.204.5.51.8.2II201414.93.21.93.2III201414.93.21.93.2III201414.93.21.93.2III201918.01.60.22.5III201918.01.60.23.81.8II20					8.2	/1.5		57				[37]
0140140140161.52.4590.6024.55ADM0111651.62.450.024.55ADM0121851.082.20.30.04.5ADM0141611.26.601.4ETest0141026.803.206.801.401119007.501.4ETest0111872.10.07.501.4ETest0111872.10.07.50.11.4ETest0111872.10.07.50.11.4ETest10191872.10.07.50.11.4ETest10191872.10.07.51.8ETestETest101919218.72.10.04.51.8ETest10191921.30.04.51.8ETestETest10191931.90.22.51.8ETestETest10191010.60.27.92.5ETestETest10191010.60.27.92.5ETestETest10141010.02.51.81.81.8DDM10141011.91.9ETestETestETest10141011.91.91.9ETestETes	20142128.596.30					0	44.5						[38]
outh Korea213161.52.4550702.455ADM2013150-6-ADM201418510.82.20.30.05ADM20141026.802.306.80FTest20141026.807.501.4FTest20111872.107.501.4FTest20091872.107.501.4FTest20091872.107.501.4FTest20144.64.7.854.37.3.94.3-FTest20141783.55.31.77.81.2ADM20101783.53.51.2ADMFTest20101783.504.51.8.25.81.8.2FTest2014491.204.51.8.21.93.21.93.2FTest2014413.504.51.8.29.13.2FTestFTest20141.31.3.97.81.51.5FTestFTestFTest20141.11.92.51.65.81.81.8DDM20142012.69.13.83.81.81.8DDM20142012.69.13.85.81.81.8FTest2014201 <td>outh Korea20131651.152.455.702.4.55ADM20131081.082.20.05ADM20141611.236.620141026.803.2306.8020141026.803.2306.802011100007.501.4.4E-Test20101872.103.7.491.2-akistan2012178363.7891.2-ADM2010923.324.8-E-Test-2010923.204.51.8.2DDM-201214918.204.51.8.2DDM-2014403.202.51.8.2E-Test-20141493.201.69.13.220141493.202.51.8.220141493.21.702.3.5E-Test-20141493.306.95.81.8.420141493.306.95.81.8.420141002.91.8.41.9.4020141011.920141011</td> <td></td> <td>[39]</td>	outh Korea20131651.152.455.702.4.55ADM20131081.082.20.05ADM20141611.236.620141026.803.2306.8020141026.803.2306.802011100007.501.4.4E-Test20101872.103.7.491.2-akistan2012178363.7891.2-ADM2010923.324.8-E-Test-2010923.204.51.8.2DDM-201214918.204.51.8.2DDM-2014403.202.51.8.2E-Test-20141493.201.69.13.220141493.202.51.8.220141493.21.702.3.5E-Test-20141493.306.95.81.8.420141493.306.95.81.8.420141002.91.8.41.9.4020141011.920141011												[39]
20131506-ADM20121851.042.23.030.0520141011.2-3.620140.016.802.30.06.80-20140.026.802.506.80-20111872.103.40120091872.103.40120121783.63.78.92.220144.64.7.85.4.37.94.320121783.63.91.1.720149.82.53.91.1.710149.83.51.5-1.8.310141.13.302.69.13.3101420191.83.306.95.81.8.410141.03.306.95.81.8.410141.01.010141.01.010141.0	2013 150 6 ADM 2014 161 1.2 36.6 Frest ADM 2014 161 1.2 36.6 Frest ADM 2014 102 6.8 0 32.3 0 6.8 0 Frest 2011 187 2.1 0 37.4 0 1 Frest Frest 2019 187 2.1 Frest												[40]
and box201210810.230.30.050.0ADM4dalysia20141026.032.306.806.76.72011107007.5014.46.76.720091872.17.5014.46.76.720091872.17.77.94.37.76.72012178363789127.77.020144.67.32.14.37.77.94.37.720144.67.32.14.37.87.37.37.320144.67.37.891.27.77.02012178363.78.91.27.87.72012181.304.59.18.27.720144.81.33.24.93.27.77.72019314.93.24.93.27.77.72019331.57.77.47.77.77.720146113.502.79.47.77.720141.01.602.97.77.77.720142012.619.27.77.77.77.720142012.719.503.79.97.77.720142011.71.71.97	201218510.82.230.30.05	outh Korea			11.5		50.7	0	24.55				[41]
adalaysia20141611.2366FrestFrest20140.00.07.501.4E.Test20141.872.103.401.E.Test20144.64.7.85.4.37.3.94.3FrestFrest20144.64.7.85.4.37.3.94.3FrestADM20121.73.63.78.91.2FrestADM20144.64.7.85.4.37.3.94.3FrestADM20144.64.7.85.4.37.3.94.3FrestADM20144.64.7.83.91.1.7FrestADM20144.62.3.53.91.1.7FrestDDM20146.12.3.304.2.69.13.3Frest20146.12.3.301.7.60.2.5.5FrestFrest20146.13.301.7.60.2.5.5FrestFrest1.31.6.61.6.67.58.3.85.3.81.3.81.3.8DDM1.41.0.11.1.11.9FrestFrestFrestFrest1.41.1.11.9FrestFrestFrestFrest1.41.1.11.9FrestFrestFrestFrest1.41.1.11.9FrestFrestFrestFrest1.41.1.11.9FrestFrest <td< td=""><td>104 11 12 36.6 Image: state state</td><td></td><td>2013</td><td>150</td><td></td><td>6</td><td></td><td></td><td></td><td></td><td></td><td>ADM</td><td>[42]</td></td<>	104 11 12 36.6 Image: state		2013	150		6						ADM	[42]
dalaysia20141026.8032.306.80E-Test201190075.5014.4E-Test20091872.1-E-TestE-Test20144647.854.37.94.3E-Test20144647.854.37.94.3E-Test201217.836378912E-Test20144647.85.37.91.2DDM2014923.324.8E-Test20144912.30.045.518.2DDM201214918.20.045.518.2E-Test201441.03.241.93.217.6E-Test20193114.193.241.93.2E-Test20293813.5TF-TestF-Test203018.010.6026.79.4E-TestPAR20102619.2E-TestE-TestAdiand201310.619.25.818.813.8Diff10.229.25.5E-TestFreat201319.858.872.883.853.818.4Adiand201320.019.2E-TestE-TestAdiand201410.11.9E-TestE-TestAdiand201219.80.002.00ADMZi	falaysia20141026.8032.306.80E.Test2011900075.5014.4E.TestE.Test20091872.1037.401E.TestE.Test20144.647.854.373.94.3E.TestE.Test20144.647.854.373.94.3E.TestE.Test20144.647.854.373.91.2E.TestD.D.M20149223.324.8E.TestE.Test20149418.204.5.518.2D.D.ME.Test20122.6121.304.5.69.13.3D.D.ME.Test2009314.1.93.24.1.93.2E.TestE.Test2009314.1.93.2026.79.4E.TestE.Test200918.010.6026.79.4E.TestE.TestE.Test7420102.619.2E.TestE.TestE.TestE.Test7420102.619.22.69.58.18.413.8D.D.M7410.33.306.95.813.813.8D.D.M7420102.619.22.60A.D.M14.47420137719.510.44002.50A.D.M742014 <td></td> <td>2012</td> <td>185</td> <td>10.8</td> <td>2.2</td> <td>30.3</td> <td>0.05</td> <td></td> <td></td> <td></td> <td>ADM</td> <td>[43]</td>		2012	185	10.8	2.2	30.3	0.05				ADM	[43]
dalaysia20141026.8032.306.80E.Test2011900075.5014.4E.Test20091872.1E.TestE.Test20201872.1E.TestE.Test20314.785.4.37.394.3E.Test20421783.63.7891.2ADM20109.23.324.8E.Test20144.69.324.3DDM201214918.20.04.518.2E.Test20144.63.30.117.602.5.5E.Test20093.813.5ADM20146.13.5.3017.602.5.5E.Test20146.13.5.3017.602.5.5E.Test20146.13.5.3017.602.5.5E.Test20146.13.5.3017.602.5.5E.Test20146.11.02.5E.TestADM20141.02.9E.Test20141.01.01.020141.01.020141.01.0<	falaysia 2014 1002 6.8 0 32.3 0 6.8 0 ETest 2011 90 0 0 75. 0 14.4 ETest 2009 187 2.1 0 37.4 0 1 ETest 2009 187 2.1 0 37.4 0 1 ETest akistan 2012 178 36 37 89 12 ETest DDM 2010 92 33 2.0 45.5 18.2 DDM ETest 2012 614 18.2 0 45.5 18.2 DDM DDM 4044 98 32.3 0 17.6 9.2.5 ETest DDM 2009 38 13.5 T ADM DDM ETest ETest 104a 2009 18.0 10.6 0 2.5 ETest ETest 104a 2010 2.6 19.2 T ADM ETest ETest 104a 0 0		2014	161	1.2		36.6					E-Test	[44]
2011 90 0 755 0 144 ETest 2011 187 2.1 0 37.4 0 1 E-Test 2014 4.6 47.8 54.3 73.9 4.3 E-Test 2014 4.6 47.8 54.3 73.9 4.3 E-Test 2010 9.2 3.3 2.0 48 E-Test E-Test 2010 9.2 3.3 2.0 48 E-Test DDM 2010 9.2 3.3 0.0 42.6 9.1 3.3 E-Test 1014 8.1 19.3 0.2 4.9 3.2 18.2 E-Test 1020 3.8 13.8 0 17.6 0 2.5 E-Test 1041 10.6 0.2 2.6 E-Test E-Test 1041 2010 10.6 0 2.6 9.2 18.4 E-Test 1041 10.1 1.9 E	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Ialaysia	2014	102	6.8	0	32.3	0	6.8	0		E-Test	[45]
201 187 2.1 0 37.4 0 1 ETest ETest 204 46 47.8 54.3 73.9 4.3 ETest ETest 201 0.2 178 36 37 89 12 ADM 201 0.2 33 2.9 41.7 ETest DDM 2014 48 2.0 45.5 1.8.2 ETest DDM 2012 149 18.2 0 45.5 1.8.2 ETest 2019 33 41.9 3.2 41.9 3.2 ETest DDM 2019 33 13.6 17.6 0 2.5 ETest 2039 13.0 10.6 0 2.7 9.4 ETest 141 0.1 0.6 0 2.7 9.4 ETest 154 10.1 0.7 9.8 1.8 1.8 1.8 DDM 161a 201 20 19.2 5.8 18.4 18.4 DDM 161a 1.1	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$,	2011	90	0	0	75.5		0	14.4		E-Test	[46]
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	2009 187 2.11 E.Test E.Test 2014 4.6 47.8 54.3 73.9 4.3 E.Test E.Test 2010 92 33 2 48 E.Test E.Test 2010 92 33 2 48 E.Test E.Test 2012 149 18.2 0 45.5 18.2 E.Test 1012 149 18.2 0 45.5 18.2 E.Test 2009 38 13.5							0					[47]
204 46 47.8 54.3 73.9 4.3 ETest 2012 178 36 37 89 12 ADM 2010 92 33 2 48 ETest DDM 2014 98 235 3.9 11.7 DDM 2012 149 18.2 0 45.5 18.2 ETest 2009 38 13.5	2014 46 47.8 54.3 73.9 4.3 E.Test 2012 178 36 37 89 12 ADM 2010 92 33 2 48 E.Test DDM 2014 98 23.5 3.9 11.7 DDM DDM 2012 149 18.2 0 45.5 18.2 E.Test DDM 2019 31 41.9 3.2 41.9 3.2 E.Test ADM 2009 38 13.5 ADM E.Test ADM awan 2014 61 35.3 0 17.6 0 23.5 E.Test Afa 2010 26 19.2 E.Test E.Test Afa 2010 26 19.2 E.Test E.Test Afa 2013 77 19.5 10.4 0 0 ADM Catamal 2012 203					0	07.11	Ū	-				[48]
Pakistan 2012 178 96 37 89 12 ADM 2010 92 33 2 48 Image: Second Sec	akistan 2012 178 36 37 89 12 ADM 2010 92 33 2 48 File File 2014 98 2.5 3.9 11.7 DDM 2012 149 18.2 0 45.5 18.2 E-Test 2009 38 13.2 11.7 ADM DDM 2009 38 13.2 19 3.2 19 3.2 aiwan 2014 61 35.3 0 17.6 0 23.5 E-Test hailand 2009 120 29.2 E-Test PCR E-Test hailand 2014 80 88.8 72.5 83.8 53.8 13.8 DDM Yetnam 2013 103 33 0 69.9 5.8 18.4 E-Test reta 2014 50 10.4 40 0 20 ADM tothamerica 2011 39 8 0 51 20 ADM totada <t< td=""><td></td><td></td><td></td><td></td><td>54.3</td><td>73.0</td><td>13</td><td></td><td></td><td></td><td></td><td>[49]</td></t<>					54.3	73.0	13					[49]
2010 92 33 2 48 E-Test 2014 98 235 3.9 11.7 DDM Furkey 2012 46 21.3 0.0 42.6 9.1 3.3 DDM Furkey 2012 61 21.3 0.0 42.6 9.1 3.3 DDM 2009 38 1.19 3.2 Image ADM Image ADM Faiwan 2014 61 35.3 0 17.6 0 23.5 E-Test Faiwan 2014 61 35.3 0 17.6 0 23.5 E-Test Faiwan 2014 61 95.8 72.6 83.8 53.8 13.8 13.8 DDM Cietam 2014 80 58.8 72.5 83.8 53.8 13.8 13.8 DDM Cietam 2014 54 11.1 1.9 2 2 3 3 3 3	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	alcietan											
2014 98 23.5 3.9 1.7 DDM 2012 149 18.2 0 45.5 18.2 E-Test 2009 31 41.9 3.2 41.9 3.2 E-Test 2009 38 13.5 E-Test ADM Faiwan 2014 61 35.3 0 17.6 0 25.5 E-Test Faiwan 2009 120 29.2 E-Test E-Test E-Test JAE 2010 26 19.2 E-Test E-Test E-Test JAE 2010 26 19.2 E-Test E-Test E-Test JAE 2013 0.6 58.8 73.8 13.4 DDM E-Test South American 2013 10.3 30 0 69.9 5.8 18.4 E-Test Colombia 2011 77 19.5 10.4 40 0 ADM Colombia 201 64 <td>$\begin{array}{cccccccccccccccccccccccccccccccccccc$</td> <td>akistan</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>12</td> <td></td> <td></td> <td></td> <td></td> <td>[50]</td>	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	akistan						12					[50]
Purkey201214918.2045.518.218.2E-TestPurkey20126121.3042.69.13.3DDM20093813.5													[51]
Purkey20126121.3042.69.13.3DDM20093141.93.241.93.2F.TestADM20093813.5ADME.TestADM200918010.6026.79.4E.Testhailand200912029.2E.TestPCRAL20102619.2E.TestE.Testndia20148058.872.583.853.813.813.8DDM/ietnam20145411.11.9E.TestE.Testrazil20137719.510.4400230ADM2010201058130230ADMcolombia20137719.510.4400230ADMcolombia2013798.90.035.403.8E.Testcolombia2010401085E.TestPCRcolombia2011905.519E.TestPCRcolombia2011905.519E.TestPCRcolombia2011905.519E.TestPCRcolombia2011905.519E.TestPCRcolombia2011905.519E.TestPCRcolombia2011905.519E.TestPCRcolombia <td>urkey 2012 61 21.3 0 42.6 9.1 3.3 DDM 2009 31 41.9 3.2 41.9 3.2 ADM aiwan 2014 61 35.3 0 17.6 0 23.5 E-Test hailand 2009 180 10.6 0 26.7 9.4 E-Test JAE 2010 26 19.2 E-Test E-Test E-Test Idia 2014 80 58.8 72.5 83.8 53.8 13.8 DDM rietam 2013 77 19.5 10.4 40 0 23 ADM colt America 2011 77 19.5 10.4 40 0 ADM ADM colt Aba 2012 203 19.8 20.5 Image: ADM ADM ADM colt Aba 2012 203 19.8 20.5 Image: ADM ADM Image: ADM Image: AD</td> <td></td> <td>[52]</td>	urkey 2012 61 21.3 0 42.6 9.1 3.3 DDM 2009 31 41.9 3.2 41.9 3.2 ADM aiwan 2014 61 35.3 0 17.6 0 23.5 E-Test hailand 2009 180 10.6 0 26.7 9.4 E-Test JAE 2010 26 19.2 E-Test E-Test E-Test Idia 2014 80 58.8 72.5 83.8 53.8 13.8 DDM rietam 2013 77 19.5 10.4 40 0 23 ADM colt America 2011 77 19.5 10.4 40 0 ADM ADM colt Aba 2012 203 19.8 20.5 Image: ADM ADM ADM colt Aba 2012 203 19.8 20.5 Image: ADM ADM Image: ADM Image: AD												[52]
A 2009 31 41.9 3.2 41.9 3.2 41.9 3.2 41.9 3.2 41.9 3.2 41.9 3.2 41.9 3.2 ADM Paiwan 2014 61 35.3 0 17.6 0 23.5 E-Test Paiwan 2009 120 29.2 PCR E-Test JAE 2010 26 19.2 E-Test E-Test JAE 2014 80 58.8 72.5 83.8 53.8 13.8 DDM Vietnam 2013 103 33 0 69.9 5.8 18.4 E-Test South American 2013 77 19.5 10.4 40 0 23 0 ADM Colombia 2012 203 19.8 20.5 ADM ADM ADM Cuba 2010 40 10 85 E-Test PCR Per 2013 77 9.5 19 E-Test PCR Vinguay 2009 79	2009 31 41.9 3.2 41.9 3.2 E-Test ADM 2009 38 13.5 ADM ADM ADM aiwan 2014 61 35.3 0 17.6 0 23.5 E-Test hailand 2009 120 29.2 PCR E-Test PCR JAE 2010 26 19.2 E-Test E-Test dia 2014 80 58.8 72.5 83.8 53.8 13.8 DDM rietnam 2013 103 33 0 69.9 5.8 18.4 E-Test irazil 2013 77 19.5 10.4 40 0 ADM colombia 2012 203 19.8 20.5 0 ADM ADM colombia 2012 203 19.8 20.5 0 ADM ADM colombia 2012 203 19.8 20.5 DDM ADM ADM colombia 2011 90 5.5 19 E-Test												[53]
2009 38 13.5 ADM Iaiwan 2014 61 35.3 0 17.6 0 23.5 E-Test Ibailand 2009 180 10.6 0 26.7 9.4 E-Test JAE 2010 26 19.2 E-Test E-Test India 2014 80 58.8 72.5 83.8 53.8 13.8 DDM Vietnam 2013 103 33 0 69 5.8 13.8 13.8 DDM Vietnam 2013 77 19.5 10.4 40 0 23 0 ADM South American 2011 39 8 0 51 0 23 0 ADM Colombia 2012 203 19.8 20.5 E-Test PCR Yeru 2010 97 8.9 0 35.4 0 3.8 E-Test Yeru 2011 96 3	aiwan 2009 38 13.5 ADM aiwan 2014 61 35.3 0 17.6 0 23.5 E-Test hailand 2009 180 10.6 0 2.67 9.4 E-Test hAE 2010 2.6 19.2 E-Test E-Test Idia 2014 80 58.8 72.5 83.8 53.8 13.8 DDM rietham 2013 103 33 0 69.9 5.8 18.4 E-Test rietham 2013 77 19.5 10.4 40 0 2.3 0 ADM reazil 2013 77 19.5 10.4 40 0 2.3 ADM ADM colombia 2012 203 19.8 20.5 ADM ADM ADM ADM ADM DDM	urkey	2012	61	21.3	0	42.6	9.1	3.3			DDM	[54]
Taiwan20146135.3017.6023.5E-Test200918010.6026.79.4E-TestHailand200912029.2E-TestE-TestIdia20102619.2E-TestE-TestIndia20148058.872.583.853.813.813.8DMVietnam201310330069.95.818.4E-TestSouth American20145411.11.9E-TestE-TestBrazil20137719.510.44002.50ADM20145411.11.9E-TestPCRADM201139805102.50ADMColombia201220319.820.5E-TestPCRPeru20104010S5.403.8E-TestPeru2011905.519E-TestPCRVorth America102.59.41.08.8E-TestCanada20199.45719E-TestPCRCanada2013108108.5019E-TestNited States2013108108.810.1DDMVietram201316.4068.8DDMDDMVietram201264068.8DDMDDM <td>aiwan 2014 61 35.3 0 17.6 0 23.5 E-Test hailand 2009 180 10.6 0 26.7 9.4 E-Test hailand 2009 120 29.2 E-Test E-Test ndia 2014 80 58.8 72.5 83.8 53.8 13.8 13.8 DDM outh American 2014 54 11.1 1.9 E-Test E-Test 10.4 40 0 ADM 0 ADM 10.4 10.9 10.4 40.0 0 ADM 10.4 10.0 10.4 10.0 10.4 10.0 10.4 10.0 10.4 10.0 10.4 10.0 10.4 10.0 10.4 10.0</td> <td></td> <td>2009</td> <td>31</td> <td>41.9</td> <td>3.2</td> <td>41.9</td> <td>3.2</td> <td></td> <td></td> <td></td> <td>E-Test</td> <td>[55]</td>	aiwan 2014 61 35.3 0 17.6 0 23.5 E-Test hailand 2009 180 10.6 0 26.7 9.4 E-Test hailand 2009 120 29.2 E-Test E-Test ndia 2014 80 58.8 72.5 83.8 53.8 13.8 13.8 DDM outh American 2014 54 11.1 1.9 E-Test E-Test 10.4 40 0 ADM 0 ADM 10.4 10.9 10.4 40.0 0 ADM 10.4 10.0 10.4 10.0 10.4 10.0 10.4 10.0 10.4 10.0 10.4 10.0 10.4 10.0 10.4 10.0		2009	31	41.9	3.2	41.9	3.2				E-Test	[55]
209 180 10.6 0 26.7 9.4 E-Test Fhaland 200 120 29.2 FCR E-Test JAE 2010 26 19.2 E-Test E-Test India 2014 80 58.8 72.5 83.8 53.8 13.8 DDM Vietnam 2013 103 33 0 69.9 5.8 18.4 E-Test South American 2014 54 11.1 1.9 A A 0 ADM South American 2013 77 19.5 10.4 40 0 23 0 ADM Colombia 2013 77 19.5 10.4 40 0 23 0 ADM Colombia 2012 203 19.8 20.5 20 ADM ADM Cuba 2010 40 10 85 2 6.9 ADM ADM Cuba 2010 77 8.9 0 35.4 0 3.8 E-Test Streac	$\begin{array}{c c c c c c c c c c c c c c c c c c c $		2009	38	13.5							ADM	[56]
Initiand 2009 120 29.2 PCR JAE 2010 26 19.2 E-Test India 2014 80 58.8 72.5 83.8 53.8 13.8 13.8 DDM Vietnam 2013 103 103 69.9 5.8 18.4 13.8 DDM Vietnam 2014 54 11.1 1.9 8 0 0 ADM Statistical 2012 203 19.5 10.4 40 0 0 ADM Colombia 2012 203 19.8 0.5 10 23 0 ADM Cuba 2011 95 19.8 20.5 PCR PCR Peru 2011 95 19.8 0 3.8 PCR PCR Vorth America 2011 90 5.5 19 PCR PCR Vaca 2011 90 5.5 19 PCR PCR Canada 2019 42 57 PCR PCR PCR	hailand 2009 120 29.2 PCR JAE 2010 26 19.2 E-Test ndia 2014 80 58.8 72.5 83.8 53.8 13.8 DDM E-Test riditam 2013 103 33 0 69.9 5.8 18.4 E-Test outh American 2014 54 11.1 1.9 E-Test 0 ADM prazi 2013 77 19.5 10.4 40 0 23 0 ADM colombia 2012 203 19.8 20.5 E-Test E-Test Clombia 2011 9 8 0 51 0 23 0 ADM cruba 2011 90 8.9 0.51 10.9 23 0 35.4 0 3.8 E-Test Cluba 2011 90 5.5 19 E-Test E-Test Cluba 2011 90 5.5 19 E-Test DDM Cluba 2013 <	aiwan	2014	61	35.3	0	17.6	0	23.5			E-Test	[57]
Indiand200912029.2PCRJAE20102619.2E-TestIndia20148058.872.583.853.813.813.8DDMVietnam20131033.8069.95.818.4DEMTestSouth American20145411.11.9F-TestE-TestDDMBrazi20137719.510.4400230ADMColombia201220319.820.5TestFCRPCRCuba2011957576FCRPCRPeru20119595.403.8ColombiaE-TestVieta79.519FCRPCRPCRPeru20119579FCRFCRPCRVieta708.9035.403.8E-TestVieta708.97035.403.8E-TestVieta70905.519FCRFCRCanada20094257FCRADMVieta709.8015FCRVieta709.8105.5015Vieta7085015FCRCanada20094257FCRADMVieta7085015FCRVieta706695100F	hailand 2009 120 29.2 FTest AE 2010 26 19.2 FTest ndia 2014 80 58.8 72.5 83.8 53.8 13.8 DDM FTest ndia 2013 103 33 0 69.9 5.8 18.4 ETest FTest outh American 2014 54 11.1 1.9 FTest 6.7 0 ADM irrazil 2013 77 19.5 10.4 40 0 23 0 ADM irrazil 2012 203 19.8 20.5 ETest FTest PCR irrazil 2012 203 19.8 20.5 10 23 DM DM irrazil 2011 95 10 35.4 0 3.8 ETest FTest irrazil 2011 90 5.5 19 ETest ETest DM irrazil 2011 66 30 2 0 15 ETest DDM		2009	180	10.6	0	26.7		9.4			E-Test	[58]
JAE 2010 26 19.2 E-Test ndia 2014 80 58.8 72.5 83.8 53.8 13.8 13.8 DDM Vietnam 2013 103 0 69.9 5.8 18.4 E-Test South American 2013 77 19.5 10.4 40 0 0 ADM Brazil 2013 77 19.5 10.4 40 0 23 0 ADM Colombia 2012 203 19.8 0.51 0 23 0 ADM Cuba 2011 39 8 0 51 0 23 0 ADM Cuba 2010 40 10 85 - F-Test PCR Peru 2011 95 - 36.9 35.4 0 3.8 E-Test Virguay 2009 79 8.9 0 35.4 0 3.8 E-Test Canada 2009 42 57 - E-Test DDM C	JAE 2010 26 19.2 E-Test ndia 2014 80 58.8 72.5 83.8 53.8 13.8 13.8 DDM Vietnam 2013 103 33 0 69.9 5.8 18.4 E-Test outh American 2014 54 11.1 1.9 E-Test 0 ADM virazil 2013 77 19.5 10.4 40 0 23 0 ADM John 39 8 0 51 0 23 0 ADM John 19 8 0.5 5 0 ADM ADM ADM John 10 40 10 85 E-Test E-Test PCR Cuba 2010 40 10 85 0 3.8 E-Test DDM Virguay 2009 79 8.9 0 35.4 0 3.8 E-Test DDM Jorth America 2011 90 5.5 19 E-Test E-Test DD	hailand	2009	120	29.2								[59]
ndia 2014 80 58.8 72.5 83.8 53.8 13.8 13.8 DDM Vietnam 2013 103 33 0 69.9 5.8 18.4 E-Test South American 2014 54 11.1 1.9 8 0 0 ADM Brazil 2013 77 19.5 10.4 40 0 0 ADM Colombia 2012 203 19.8 20.5 0 23 0 ADM Cuba 2010 40 10 85 2.5 E-Test PCR Cuba 2011 95 . 35.4 0 3.8 E-Test Peru 2011 95 . . 3.8 E-Test PCR Vorth America .	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$												[60]
Vietnam 2013 103 33 0 69.9 5.8 18.4 E-Test South American 2014 57 10.1 1.9 E-Test E-Test Brazil 2013 77 19.5 10.4 40 0 0 ADM Colombia 2012 203 19.8 20.5 23 0 ADM Cuba 2010 40 10 8 0 51 0 23 0 ADM Cuba 2010 40 10 8 5 E-Test PCR Peru 2011 95 9 8.9 0 35.4 0 3.8 E-Test Jurguay 2009 79 8.9 0 35.4 0 3.8 E-Test Canada 2009 42 57 E-Test E-Test Canada 2009 42 57 E-Test DDM Stenegal 2013 <	Tietnam 2013 103 33 0 69.9 5.8 18.4 E-Test outh American 2014 54 11.1 1.9 E-Test E-Test prazil 2013 77 19.5 10.4 40 0 0 ADM colombia 2012 203 19.8 0.5 51 0 23 0 ADM colombia 2012 203 19.8 20.5 23 0 ADM colombia 2012 203 19.8 20.5 20.9 ADM ADM colombia 2010 40 10 85 E E E F cuba 2011 95 36.9 ADM DDM DDM creru 2011 90 5.5 19 E E F E canada 2009 42 57 E E ADM ADM canada 2011 686 30 2 42 0 19 E ADM <td></td> <td></td> <td></td> <td></td> <td>72 5</td> <td>83.8</td> <td>53.8</td> <td>13.8</td> <td></td> <td>13.8</td> <td></td> <td>[61]</td>					72 5	83.8	53.8	13.8		13.8		[61]
South American 2014 54 11.1 1.9 E-Test brazil 2013 77 19.5 10.4 40 0 0 ADM 2011 39 8 0 51 0 23 0 ADM 2010 203 10.8 20.5 E-Test PCR PC	South American 2014 54 11.1 1.9 E-Test arazil 2013 77 19.5 10.4 40 0 ADM 2011 39 8 0 51 0 23 0 ADM 2010 39 8 0 51 0 23 0 ADM 2010 40 10 85 - E-Test PCR Cuba 2010 40 10 85 -<										15.0		[62]
2014 54 11.1 1.9 \mathbb{P}	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$		2015	105	33	0	09.9	5.0	10.4			1-1050	[02]
Brazil 2013 77 19.5 10.4 40 0 0 ADM 2011 39 8 0 51 0 23 0 ADM Colombia 2012 203 19.8 20.5 Person ADM ADM Cuba 2010 40 10 85 Feat Feat PCR Peru 95 79 8.9 0 35.4 0 3.8 E-Test Uruguay 2009 79 8.9 0 35.4 0 3.8 E-Test Canada 2009 42 57 E-Test E-Test ADM Canada 2009 42 57 E-Test ADM Senegal 2011 686 30 2 42 0 19 E-Test Niferia 2009 186 66 95 100 E-test DDM Senegal 2010 201 64 0 68.8 ADM ADM South Africa 2010 273	razil 2013 77 19.5 10.4 40 0 0 ADM 2011 39 8 0 51 0 23 0 ADM 2010 2012 203 19.8 20.5 E-Test PCR 2010 2010 10 85 E-Test PCR 2010 2011 95 36.9 ADM DDM Preu 2011 95 19 E-Test PCR Vorth America	Julii American	0014	F 4	11.1	1.0						E Teet	I co
20113980510230ADMColombia201220319.820.5 20.5 20.5 20.5 ADM Cuba20104010 $85.$ $E.Test$ PCR Peru201195 36.9 ADM DDM Jruguay2009798.90 35.4 0 3.8 $E.Test$ Vorth America2011905.519 $E.Test$ ADM Mexico2011905.519 $E.Test$ Juited States2010686302 42 019 $E.Test$ Senegal20131081085015 DDM Nigeria20091866695100 $E.test$ DDM South Africa201027315.4051.3 $E.test$ Gouth Africa201020097.5 $E.test$ ADM	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$.1					10	0			0		[63]
Colombia 2012 203 19.8 20.5 ADM Cuba 2010 40 10 85 E-Test PCR Peru 2011 95 36.9 ADM DDM Jruguay 2009 79 8.9 0 35.4 0 3.8 E-Test Vorth America 10 5.5 19 E-Test E-Test Varido 2011 90 5.5 19 E-Test Canada 2009 42 57 E-Test ADM Varido 2011 90 5.5 0 15 E-Test Senegal 2013 108 1 0 85 0 15 E-test Sambia 202 64 0 68.8 ADM ADM ADM Sambia 2010 273 15.4 0 51.3 E-test ADM South Africa 2010 200 97.5 XDM	Colombia 2012 203 19.8 20.5 ADM Cuba 2010 40 10 85 E-Test PCR Peru 2011 95 36.9 ADM DDM Jurguay 2009 79 8.9 0 35.4 0 3.8 E-Test DDM Varguay 2009 79 8.9 0 35.4 0 3.8 E-Test DDM Varguay 2009 79 8.9 0 35.4 0 3.8 E-Test DDM Varguay 2009 42 57 E-Test DDM	razii							-				[64]
Cuba 2010 40 10 85 E-Test PCR Peru 2011 95 36.9 ADM Peru 2009 79 8.9 0 35.4 0 3.8 E-Test Juguay 2009 79 8.9 0 35.4 0 3.8 E-Test Vorth America E-Test Vexico 2011 90 5.5 19 E-Test Canada 2009 42 57 E-Test ADM Canada 2011 68 30 2 42 0 19 E-Test Genegal 2013 188 1 0 85 0 15 E-test Vigeria 2009 186 66 95 100 E-test DDM Sambia 2012 64 0 68.8 ADM ADM South Africa 2010 203 15.4 0 51.3 E-test Gambia 2010 203 15.4 0 51.3 E-test	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$						51	0	23		0		[65]
Peru 2011 95 36.9 ADM Jruguay 2009 79 8.9 0 35.4 0 3.8 E-Test North America 1 90 5.5 19 E-Test E-Test Canada 2009 42 57 E-Test E-Test Jnited States 2011 686 30 2 42 0 19 E-Test Senegal 2013 108 1 0 85 0 15 E-test Nigeria 2009 186 66 95 100 E-test DDM Gambia 2012 64 0 68.8 ADM E-test ADM Guith Africa 2010 203 15.4 0 51.3 E-test Gouth Africa 2010 200 97.5 ADM E-test	Peru 2011 95 36.9 ADM Uruguay 2009 79 8.9 0 35.4 0 3.8 E-Test Vorth America 1 90 5.5 19 E-Test E-Test Canada 2009 42 57 E-Test E-Test Vinted States 2011 686 30 2 42 0 19 E-Test Vinted States 2013 108 1 0 85 0 15 E-test DDM Vigeria 2009 186 66 95 100 E-test DDM Sambia 2010 273 15.4 0 51.3 E-test DDM Outh Africa 2010 200 97.5 E-test DDM E-test	olombia	2012	203	19.8	20.5						ADM	[66]
Peru 201 95 36.9 ADM Uruguay 2009 79 8.9 0 35.4 0 3.8 E-Test North America 1 90 5.5 19 E-Test E-Test Canada 2009 42 57 E-Test E-Test United States 2011 686 30 2 42 0 19 E-Test Senegal 2013 108 1 0 85 0 15 E-test Nigeria 2009 186 66 95 100 E-test DDM Gambia 2012 64 0 68.8 ADM E-test ADM Gunisia 2010 273 15.4 0 51.3 E-test ADM	Peru 2011 95 36.9 ADM Uruguay 2009 79 8.9 0 35.4 0 3.8 E-Test Vorth America 1 90 5.5 19 E-Test E-Test Canada 2009 42 57 E-Test E-Test Vinted States 2011 686 30 2 42 0 19 E-Test Vinted States 2013 108 1 0 85 0 15 E-test DDM Vigeria 2009 186 66 95 100 E-test DDM Sambia 2010 273 15.4 0 51.3 E-test DDM Outh Africa 2010 200 97.5 E-test DDM E-test												
Peru 2011 95 36.9 ADM Uruguay 2009 79 8.9 0 35.4 0 3.8 E-Test Vorth America 1 90 5.5 19 E-Test E-Test Canada 2009 42 57 E-Test E-Test United States 2011 686 30 2 42 0 19 E-Test Senegal 2013 108 1 0 85 0 15 E-test Nigeria 2009 186 66 95 100 E-test DDM Gambia 2012 64 0 68.8 ADM E-test Gambia 2010 273 15.4 0 51.3 E-test Gouth Africa 2010 200 97.5 ADM E-test	Peru 2011 95 36.9 ADM Jruguay 2009 79 8.9 0 35.4 0 3.8 E-Test Jruguay 2009 79 8.9 0 35.4 0 3.8 E-Test Kerico 2011 90 5.5 19 E-Test E-Test Canada 2009 42 57 E-Test ADM United States 2011 686 30 2 42 0 19 E-Test Inited States 2013 108 1 0 85 0 15 E-test DDM Inited States 2009 186 66 95 100 E-test DDM Sambia 2012 64 0 68.8 ADM E-test DDM Sumbia 2010 273 15.4 0 51.3 E-test DDM Outh Africa 2010 200 97.5 ADM DDM DDM	uba	2010	40	10		85						[67]
$\begin{array}{c c c c c c c } & & & & & & & & & & & & & & & & & & &$	Jruguay 2009 79 8.9 0 35.4 0 3.8 E-Test Vorth America Mexico 2011 90 5.5 19 E-Test Canada 2009 42 57 E-Test E-Test United States 2011 686 30 2 42 0 19 E-Test enegal 2013 108 1 0 85 0 15 E-test Sambia 2012 64 0 68.8 ADM DDM 'unisia 2010 273 15.4 0 51.3 E-test outh Africa 2010 200 97.5 ADM DDM											PCR	
$ \begin{array}{c c c c c c c } & & & & & & & & & & & & & & & & & & &$	Jruguay 2009 79 8.9 0 35.4 0 3.8 E-Test Vorth America Mexico 2011 90 5.5 19 E-Test Canada 2009 42 57 E-Test E-Test United States 2011 686 30 2 42 0 19 E-Test enegal 2013 108 1 0 85 0 15 E-test Sambia 2012 64 0 68.8 ADM DDM 'unisia 2010 273 15.4 0 51.3 E-test outh Africa 2010 200 97.5 ADM DDM	eru	2011	95					36.9			ADM	[68]
Juguay 2009 79 8.9 0 35.4 0 3.8 E-Test North America Mexico 2011 90 5.5 19 E-Test Canada 2009 42 57 E-Test E-Test United States 2011 686 30 2 42 0 19 E-Test Senegal 2013 108 1 0 85 0 15 E-test Nigeria 2009 186 66 95 100 E-test DDM Gambia 2012 64 0 68.8 ADM E-test Gambia 2010 273 15.4 0 51.3 E-test South Africa 2010 200 97.5 ADM E-test	Jruguay 2009 79 8.9 0 35.4 0 3.8 E-Test North America Mexico 2011 90 5.5 19 E-Test E-Test Canada 2009 42 57 E-Test E-Test ADM Jnited States 2011 686 30 2 42 0 19 E-Test enegal 2013 108 1 0 85 0 15 E-test Nigeria 2009 186 66 95 100 E-test DDM Sambia 2012 64 0 68.8 ADM E-test DDM 'unisia 2010 273 15.4 0 51.3 E-test DM outh Africa 2010 200 97.5 ADM DDM DDM												
North America E-Test Mexico 2011 90 5.5 19 E-Test Canada 2009 42 57 E-Test United States 2011 686 30 2 42 0 19 E-Test Senegal 2013 108 1 0 85 0 15 E-test Nigeria 2009 186 66 95 100 E-test DDM Gambia 2012 64 0 68.8 ADM E-test Gouth Africa 2010 203 15.4 0 51.3 E-test	North America E-Test Mexico 2011 90 5.5 19 E-Test Canada 2009 42 57 E-Test E-Test Jnited States 2011 686 30 2 42 0 19 E-Test enegal 2013 108 1 0 85 0 15 E-test DDM Vigeria 2009 186 66 95 100 E-test DDM Gambia 2012 64 0 68.8 ADM E-test DM 'unisia 2010 273 15.4 0 51.3 E-test DM outh Africa 2010 200 97.5 ADM DDM DDM	Iruguay	2009	79	8.9	0	35.4	0	3.8				[69]
Mexico 2011 90 5.5 19 E-Test Canada 2009 42 57 E-Test Jnited States 2011 686 30 2 42 0 19 E-Test Senegal 2013 108 1 0 85 0 15 E-test Nigeria 2009 186 66 95 100 E-test DDM Cambia 2012 64 0 68.8 ADM E-test Gouth Africa 2010 200 97.5 ADM E-test	Mexico 2011 90 5.5 19 E-Test Canada 2009 42 57 E-Test Jnited States 2011 686 30 2 42 0 19 E-Test enegal 2013 108 1 0 85 0 15 E-test Vigeria 2009 186 66 95 100 E-test DDM Sambia 2012 64 0 68.8 ADM E-test DDM 'unisia 2010 273 15.4 0 51.3 E-test DDM outh Africa 2010 200 97.5 ADM DDM DDM	0.											107.
Canada 2009 42 57 E-Test Jnited States 2011 686 30 2 42 0 19 E-Test Jenegal 2013 108 1 0 85 0 15 E-test Vigeria 2009 186 66 95 100 E-test Gambia 2012 64 0 68.8 ADM Funisia 2010 273 15.4 0 51.3 E-test Gouth Africa 2010 200 97.5 ADM	Canada 2009 42 57 E-Test Jnited States 2011 686 30 2 42 0 19 E-Test enegal 2013 108 1 0 85 0 15 E-test Vigeria 2009 186 66 95 100 E-test DDM Sambia 2012 64 0 68.8 ADM E-test DDM 'unisia 2010 273 15.4 0 51.3 E-test DDM outh Africa 2010 200 97.5 ADM DDM DDM		2011	00	5.5		19					F-Test	[70]
Jnited States 2011 686 30 2 42 0 19 E-Test Jointed States 2013 108 1 0 85 0 15 E-test Senegal 2009 186 66 95 100 E-test Sigeria 2012 64 0 68.8 ADM Gambia 2010 273 15.4 0 51.3 E-test Gouth Africa 2010 200 97.5 ADM	Jnited States 2011 686 30 2 42 0 19 E-Test ADM enegal 2013 108 1 0 85 0 15 E-test DDM Vigeria 2009 186 66 95 100 E-test DDM Sambia 2012 64 0 68.8 ADM E-test DDM 'unisia 2010 273 15.4 0 51.3 E-test DDM outh Africa 2010 200 97.5 ADM DDM DDM						19						
ADM Benegal 2013 108 1 0 85 0 15 E-test Vigeria 2009 186 66 95 100 E-test Gambia 2012 64 0 68.8 ADM Funsia 2010 273 15.4 0 51.3 Gouth Africa 2010 200 97.5 ADM	enegal 2013 108 1 0 85 0 15 E-test bigeria 2009 186 66 95 100 E-test DDM Sambia 2012 64 0 68.8 ADM 'unisia 2010 273 15.4 0 51.3 E-test outh Africa 2010 200 97.5 ADM DDM					0	10	0	10				[71]
Senegal 2013 108 1 0 85 0 15 E-test Vigeria 2009 186 66 95 100 E-test Sambia 2012 64 0 68.8 ADM Funisia 2010 273 15.4 0 51.3 E-test South Africa 2010 200 97.5 ADM ADM	energal 2013 108 1 0 85 0 15 E-test DDM Nigeria 2009 186 66 95 100 E-test DM Gambia 2012 64 0 68.8 ADM E-test DM 'unisia 2010 273 15.4 0 51.3 E-test DM outh Africa 2010 200 97.5 ADM DDM	nited States	2011	686	30	2	42	0	19				[72]
DDM Nigeria 2009 186 66 95 100 E-test Gambia 2012 64 0 68.8 ADM Funisia 2010 273 15.4 0 51.3 E-test South Africa 2010 200 97.5 ADM	DDM Nigeria 2009 186 66 95 100 E-test Gambia 2012 64 0 68.8 ADM 'unisia 2010 273 15.4 0 51.3 E-test outh Africa 2010 200 97.5 ADM DDM												
Nigeria 2009 186 66 95 100 E-test Gambia 2012 64 0 68.8 ADM Funisia 2010 273 15.4 0 51.3 E-test South Africa 2010 200 97.5 ADM	Nigeria 2009 186 66 95 100 E-test Gambia 2012 64 0 68.8 ADM Image: ADM	enegal	2013	108	1	0	85	0	15				[73]
Nigeria 2009 186 66 95 100 E-test Gambia 2012 64 0 68.8 ADM Funisia 2010 273 15.4 0 51.3 E-test South Africa 2010 200 97.5 ADM	Nigeria 2009 186 66 95 100 E-test Gambia 2012 64 0 68.8 ADM Image: ADM											DDM	
Gambia 2012 64 0 68.8 ADM Funisia 2010 273 15.4 0 51.3 E-test South Africa 2010 200 97.5 ADM	Sambia 2012 64 0 68.8 ADM Junisia 2010 273 15.4 0 51.3 E-test outh Africa 2010 200 97.5 ADM DDM	ligeria	2009	186		66	95	100					[74]
Cunisia 2010 273 15.4 0 51.3 E-test South Africa 2010 200 97.5 ADM	Yunisia 2010 273 15.4 0 51.3 E-test outh Africa 2010 200 97.5 ADM DDM				0								[75]
South Africa 2010 200 97.5 ADM	outh Africa 2010 200 97.5 ADM DDM					0							[76]
	DDM				10.4		51.5						
DDM		Julit Africa	2010	200		97.5							[77]
	2014 1651 6.7 29.4 E-test												[78]



Ghotaslou R et al. Helicobacter pylori resistance to antibiotics

Germany	2013	5296	67.1	0	67.1		24.9		E-test	[79]
	2013	436	7.5	0	32.7		11.7		E-test	[80]
Italy	2012	111	35.2		59.3		22.1		E-test	[81]
	2011	253	9.9						PCR	[82]
England	2009	255						1	E-test DDM	[83]
	2013	343	23.5		33				E-test	[84]
Spain	2011	71	14.7	1.4	45.1	0	14.5		E-test	[85]
	2010	118	35.6						E-test	[86]
	2009	101	54.6		35.7				E-test	[87]
Norway	2012	102	5.9	0	22.5	0			E-test	[88]
Finland	2010	505	8	0	41		7		E-test	[89]
	2013	588	20.1		34.5	2.6			ADM	[90]
Bulgaria	2011	519	17.9		29.5	4			ADM	[91]
	2009	1057	18.7	0.5	21.35	3.15			ADM	[92]
Croatia	2012	382	11.9	0.6	10.1				E-test	[93]
	2014	210					8.1		E-test	[94]
Poland	2013	165	10.9		32.7		1.2		E-test	[95]
	2012	51	22				16		E-test	[96]
	2011	115	34	0	44		5		E-test	[97]
Portugal	2014	180	50	0.6	34.4	0.6	33.9		E-test	[98]
	2011	1115	34.7	0	13.9	0			E-test	[99]
Belgium	2013	189	13.3	0.8	26.1					[100]
	2011	10670	20.3	0	27				ADM	[101]
Netherlands	2014	417	6.14		10.1				E-test	[102]
	2013	746	20.5	0.68	19.9				E-test	[103]
Ireland	2013	85				0	11.7	0	E-test	[104]
	2010	219	13.2		31.5				E-test	[105]
Southern Europe	2014	74	34.7		16.7				E-test	[106]

Amo: Amoxicillin; Cla: Clarithromycin; Met: Metronidazole; Tet: Tetracycline; Lev: Levofloxacin; Rif: Rifabutin; Fur: Furazolidon; DDM: Disk Diffusion Agar; ADM: Agar Dilution Agar.

preferred^[17]. At the present, due to *H. pylori* antibiotics resistance, eradication therapy appears was not carried out as simple as and we are now founded many failures which make the use of standard therapy unacceptable in many parts of the world^[107]. This article systematically studied the latest data on *H. pylori* resistance to antibiotic.

Clarithromycin resistance

Because clarithromycin is the most potent antibiotic involved in the management of *H. pylori* infections, resistance to clarithromycin is important^[8,17,105]. As presented in Table 2, the rate of clarithromycin resistance was 19.74%, and occurrence of clarithromycin resistance is increasing worldwide (Figure 2). The rate of clarithromycin resistance has been broadly studied, and information are on hand from nearly all areas in the world: it ranges from 5.46% to 30.8% (Figure 1).

In European regions, the lowest clarithromycin resistance was reported from Norway (5.9%), whilst the highest in Spain (32.01%) and Portugal (42.35%). European studies performed at the past 6 years intervals reported that *H. pylori* resistance decrease from 36.65% in 2009 to 24.38% in 2014. In Asian regions, a surprising clarithromycin resistance frequency was reported from India (58.8%) and China (46.54%), whereas the lowest rate was discovered in Malaysia (2.4%). An increase in clarithromycin resistance has been faced in the Asia, from 15.28% in 2009 to 32.46% in 2014, probably in the Asian countries macrolid

drugs used more. In recent years due to widespread use of clarithromycin for respiratory infections in the public especially in children, clarithromycin resistance has augmented in diverse regions, and there is an association between outpatient use of long-acting macrolide and clarithromycin resistance^[10,17,108].

In conclusion, the highest clarithromycin resistant area was North America, and this study showed a slight increasing tendency of clarithromycin resistance of *H. pylori* in the world. Since clarithromycin is the most potent antimicrobial agent involved in the standard treatment protocol as well as the resistance rates were still at the low level, where clarithromycin-containing triple therapies could be used empirically.

Metronidazole resistance

Metronidazole is used against *H. pylori* infections and is one of the few antibacterial agents as drug of choice that is effective in eradicated the microorganism. Some researcher reported that the rate of treatment failure is more than 20% with triple therapy in which metronidazole is the drug of choice, also *H. pylori* resistance to metronidazole is the chief solitary reason responsible for management failure^[109,110].

Metronidazole resistance is the most common antibiotic resistance in *H. pylori* and overall metronidazole resistance found in 47.22% in descending order in Africa 75.02%, South America 52.85%, Asia 46.57%, Europe 31.19%, to 30.5% in North America. In developed countries about 30% of the *H. pylori* strains






Figure 2 Trend of Helicobacter pylori resistance to metronidazole, clarithromycin, and amoxicillin during 6-years.

are metronidazole resistant, whereas in developing countries, the occurrence of resistance is very high. This association between metronidazole resistance and socioeconomic state level is maybe due to use of metronidazole and related drugs for gynecological, dental and parasitic related infectious diseases^[13,111]. The comparison of results indicated that resistance to metronidazole have remained significantly unchanging in Asian, European and North American countries but is increasing in African countries (51.3% in 2010 to 85% in 2013). Furthermore metronidazole resistance in 2014 has stayed approximately at the similar level as in early 2009 in Europe. So, in accordance with latest guidelines, metronidazole is favored to amoxicillin in first-line therapy in Asian, Europe and North American but not in African patients.

Amoxicillin resistance

Amoxicillin is suggested for anti-*H. pylori* triple therapy in region where metronidazole resistance is high. Universal resistance to amoxicillin is uncommon; it was detected in 14.67%. The frequency of amoxicillin resistance extensively differs in Asian regions, ranging from zero in Malaysia, Taiwan and Vietnam to 72.5% in India. The rate of amoxicillin resistance in Africa was 40.87%.

The prevalence of amoxicillin resistance in Europe countries and North American is low from zero in certain area as Finland, Germany, Norway and Poland, 1.4% in Spain to 2% in United States. It seems the government policy possibly to limit the use of antibiotic for infectious diseases in European and North American countries. The incidence of amoxicillin resistance in *H. pylori* seems to increase specially in Asia and South America, where these antibiotics can be obtained without prescription. *H. pylori* resistance rates of 97.5%, 72.5%, 66% and 20.5% for amoxicillin have recently been reported in South Africa, India, Nigeria and Colombia, respectively.

Tetracycline resistance

Among the 4 most common used antimicrobial agents, tetracycline resistance was the lowest (Table 3). In

general *H. pylori* resistance to tetracycline was detected 11.7% in the world. The total rate of tetracycline resistance did not vary in South America and North America (the resistance was absent), whilst it was relatively high in Africa (50%). In Asia, the resistance was absent in Thailand, and very low in China (0.6%) and South Korea (0.01%). In contrast, increased values were found in India (53.8%), and Iran (11.7%). The prevalence of tetracycline resistance stays very low (less than 7.4%) in almost most parts of the world except for Africa. The comparison of data showed that tetracycline resistance is decreasing in the world, 26.85% in 2009 to 6.11% in 2014.

Tetracycline is a bacteriostatic and broad spectrum antimicrobial agent that is active against *H. pylori* and tetracycline is the most generally used antibiotic for treatment of *H. pylori* and other infectious diseases^[109]. Tetracycline is extensively used in many countries, but resistance to this antibiotic has not become a great problem yet. Management failure owing to the tetracycline resistant has been reported^[112,113], though there is not enough data obtainable until now to determine the impact of this resistance on management success.

Rifabutin resistance

However, the study on *H. pylori* rifabutin resistance is inadequate and in South America, North America and Africa has not been done during previous 6 years. The rate of rifabutin resistance was higher in Asia (12.45%) as compared to Europe (1%). The frequency of rifabutin resistance differs in Asian countries, ranging from 28.6% in Iran to about 7% in China and Malaysia. Rifabutin is structurally related to rifampin group, and it has potential efficacy against *H. pylori*^[114]. Rifabutin is usually used to treat mycobacterium diseases, so the secondary resistance of *H. pylori* to rifabutin is not currently expected in the healthy people.

Levofloxacin resistance

Generally, resistance to levofloxacin is low (< 19%) worldwide. The prevalence rate was higher in Asia



Ghotaslou R et al. Helicobacter pylori resistance to antibiotics

(25.28%) and South America (21.23%) as compared to Africa and Europe (less than 15%). The frequency of levofloxacin resistance widely differs in Asian regions, about 57% in Japan, 24.55% in South Korea, 5.3% in Iran and 2.6% in Malaysia. In addition the levofloxacin resistance rate differs between European countries, ranging from 7% to 33.9%. The rate of levofloxacin resistance seems to be increasing universal from 4.25% in 2009 to 17.55% in 2014. Furthermore, during the past 3 years levofloxacin resistance rates have even been more increasing.

Due to the dramatic increase in clarithromycin resistance, levofloxacin, a wide spectrum quinolone, has been used as an option of clarithromycin in some regimens. But the frequent use of quinolones for urinary tract infections has increased the incidence of *H. pylori* resistance in the world^[17]. Failure of therapy due to levofloxacin resistance and the emerging development of quinolones resistance, use of levofloxacin as first-line therapy is generally discouraged, and its utilize should be reserved as a second-line or save regimens after failure of a clarithromycin and/or a metronidazole based regimen^[7,80].

Furazolidon resistance

The study on furazolidon resistance was not widely performed in the world, and in Europe, North America and Africa has not been achieved during past 6 years. The rate of furazolidon resistance was higher in Asia (13.8%) as compared to South America (0%). The rate of furazolidon resistance broadly differs in Asia, from 61.4% in Iran to 16.8% in China and 13.8% in India. Furazolidon is a cheap and synthetic nitrofuran with a wide spectrum activities usually used in the treatment of bacterial and protozoa infections. Since high H. pylori resistance to metronidazole in some region as China and South America, furazolidon sometimes has been used as an option for *H. pylori* infections^[65]. However some researchers were reported that the rate of cure with furazolidon-based regimens is low and a large amount of furazolidon increases the therapy rate but it significantly raises complications^[81].

The prevalence of *H. pylori* metronidazole resistance is at a high level, and resistance to clarithromycin and levofloxacin is increasing worldwide. The most effective drug is rifabutin and the lowest sensitive drug is metronidazole. Resistance to levofloxacin does not show any region difference. There are no studies regarding rifabutin and furazolidon resistance of H. pylori in America and Africa. According to the present findings, the mean resistance rate in *H. pylori* isolated from European and North American patients is lower than other countries. The rate of tetracycline, metronidazole and amoxicillin resistance is higher in African patients, while clarithromycin and levofloxacin resistance is higher in North America and Asian patients. In conclusion, antibiotic resistance is increasing, so empirical therapy must be based on information of antimicrobial drug

resistance, and this paper highlight a steady worldwide surveillance of *H. pylori* antibiotic resistance.

COMMENTS

Background

Helicobacter pylori (*H. pylori*) is a most important human pathogen associated with significant disease and fatality.

Research frontiers

Due to the rising frequency of antimicrobial resistance, management of *H. pylori* remains a challenge for physicians in most parts of the world.

Innovations and breakthroughs

Search was carried out about *H. pylori* antimicrobial resistance literatures published through 2009 to 2014.

Applications

The frequency of antibiotic resistance is increasing, and this article highlight a steady worldwide surveillance of *H. pylori* antibiotic resistance.

Peer-review

This is a systematic review article on *H. pylori* resistance to antibiotics. The manuscript is well written and the topic of interest.

REFERENCES

- Rafeey M, Ghotaslou R, Nikvash S, Hafez AA. Primary resistance in Helicobacter pylori isolated in children from Iran. *J Infect Chemother* 2007; 13: 291-295 [PMID: 17982716]
- 2 Ghotaslou R, Milani M, Akhi MT, Hejazi MS, Nahaei MR, Hasani A, Sharifi Y. Relationship between drug resistance and cagA Gene in Helicobacter pylori. *Jundishapur J Microbiol* 2013; 6: 8480
- 3 Ghotaslou R, Milani M, Akhi MT, Nahaei MR, Hasani A, Hejazi MS, Meshkini M. Diversity of Helicobacter Pylori cagA and vacA Genes and Its Relationship with Clinical Outcomes in Azerbaijan, Iran. Adv Pharm Bull 2013; 3: 57-62 [PMID: 24312813 DOI: 10.5681/apb.2013.010]
- 4 Gasbarrini G, Racco S, Franceschi F, Miele L, Cammarota G, Grieco A, Gasbarrini A. [Helicobacter pylori infection: from gastric to systemic disease]. *Recenti Prog Med* 2010; 101: 27-33 [PMID: 20391683]
- 5 Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. *Gut* 2007; 56: 772-781 [PMID: 17170018]
- 6 Smith SM, O'Morain C, McNamara D. Antimicrobial susceptibility testing for Helicobacter pylori in times of increasing antibiotic resistance. *World J Gastroenterol* 2014; 20: 9912-9921 [PMID: 25110421 DOI: 10.3748/wjg.v20.i29.9912]
- 7 Cammarota G, Ianiro G, Bibbò S, Di Rienzo TA, Masucci L, Sanguinetti M, Gasbarrini A. Culture-guided treatment approach for Helicobacter pylori infection: review of the literature. *World J Gastroenterol* 2014; 20: 5205-5211 [PMID: 24833850 DOI: 10.3748/wjg.v20.i18.5205]
- 8 Di Mario F, Cavallaro LG, Scarpignato C. 'Rescue' therapies for the management of Helicobacter pylori infection. *Dig Dis* 2006; 24: 113-130 [PMID: 16699270]
- 9 Seo JH, Jun JS, Yeom JS, Park JS, Youn HS, Ko GH, Baik SC, Lee WK, Cho MJ, Rhee KH. Changing pattern of antibiotic resistance of Helicobacter pylori in children during 20 years in Jinju, South Korea. *Pediatr Int* 2013; 55: 332-336 [PMID: 23279258 DOI: 10.1111/ped.12048]
- 10 **Boltin D**, Ben-Zvi H, Perets TT, Kamenetsky Z, Samra Z, Dickman R, Niv Y. Trends in secondary antibiotic resistance of Helicobacter

pylori from 2007 to 2014: has the tide turned? *J Clin Microbiol* 2015; **53**: 522-527 [PMID: 25428158 DOI: 10.1128/JCM.03001-14]

- 11 Kupcinskas L, Rasmussen L, Jonaitis L, Kiudelis G, Jørgensen M, Urbonaviciene N, Tamosiunas V, Kupcinskas J, Miciuleviciene J, Kadusevicius E, Berg D, Andersen LP. Evolution of Helicobacter pylori susceptibility to antibiotics during a 10-year period in Lithuania. *APMIS* 2013; **121**: 431-436 [PMID: 23078193 DOI: 10.1111/apm.12012]
- 12 Cameron EA, Powell KU, Baldwin L, Jones P, Bell GD, Williams SG. Helicobacter pylori: antibiotic resistance and eradication rates in Suffolk, UK, 1991-2001. *J Med Microbiol* 2004; **53**: 535-538 [PMID: 15150334]
- 13 Glupczynski Y, Mégraud F, Lopez-Brea M, Andersen LP. European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. *Eur J Clin Microbiol Infect Dis* 2001; 20: 820-823 [PMID: 11783701]
- 14 **Kist M**, Glocker E. ResiNet A nationwide German sentinel study for surveillance and analysis of antimicrobial resistance in Helicobacter pylori. *Eurosurveillance* 2004; **9**: 44-46
- 15 Koivisto TT, Rautelin HI, Voutilainen ME, Niemelä SE, Heikkinen M, Sipponen PI, Färkkilä MA. Primary Helicobacter pylori resistance to metronidazole and clarithromycin in the Finnish population. *Aliment Pharmacol Ther* 2004; 19: 1009-1017 [PMID: 15113368]
- 16 Gerrits MM, van der Wouden EJ, Bax DA, van Zwet AA, van Vliet AH, de Jong A, Kusters JG, Thijs JC, Kuipers EJ. Role of the rdxA and frxA genes in oxygen-dependent metronidazole resistance of Helicobacter pylori. *J Med Microbiol* 2004; **53**: 1123-1128 [PMID: 15496391]
- 17 De Francesco V, Giorgio F, Hassan C, Manes G, Vannella L, Panella C, Ierardi E, Zullo A. Worldwide H. pylori antibiotic resistance: a systematic review. *J Gastrointestin Liver Dis* 2010; 19: 409-414 [PMID: 21188333]
- 18 Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ. Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. *Gut* 2012; 61: 646-664 [PMID: 22491499 DOI: 10.1136/gutjnl-2012-302084]
- 19 Papastergiou V, Georgopoulos SD, Karatapanis S. Treatment of Helicobacter pylori infection: Past, present and future. *World J Gastrointest Pathophysiol* 2014; **5**: 392-399 [PMID: 25400982 DOI: 10.4291/wjgp.v5.i4.392]
- 20 Keshavarz Azizi Raftar S, Moniri R, Saffari M, Razavi Zadeh M, Arj A, Mousavi SG, Mirzaei Ghazi Kalayeh H, Dastehgoli K. The Helicobacter pylori resistance rate to clarithromycin in Iran. *Microb Drug Resist* 2015; 21: 69-73 [PMID: 25144338 DOI: 10.1089/ mdr.2014.0104]
- 21 Zendedel A, Moradimoghadam F, Almasi V, Zivarifar H. Antibiotic resistance of Helicobacter pylori in Mashhad, Iran. *J Pak Med Assoc* 2013; **63**: 336-339 [PMID: 23914633]
- 22 Khademi F, Faghri J, Poursina F, Esfahani BN, Moghim S, Fazeli H, Adibi P, Mirzaei N, Akbari M, Safaei HG. Resistance pattern of Helicobacter pylori strains to clarithromycin, metronidazole, and amoxicillin in Isfahan, Iran. *J Res Med Sci* 2013; 18: 1056-1060 [PMID: 24523796]
- 23 Talebi Bezmin Abadi A, Ghasemzadeh A, Taghvaei T, Mobarez AM. Primary resistance of Helicobacter pylori to levofloxacin and moxifloxacine in Iran. *Intern Emerg Med* 2012; 7: 447-452 [PMID: 21437583]
- 24 Milani M, Ghotaslou R, Akhi MT, Nahaei MR, Hasani A, Somi MH, Rafeey M, Sharifi Y. The status of antimicrobial resistance of Helicobacter pylori in Eastern Azerbaijan, Iran: comparative study according to demographics. *J Infect Chemother* 2012; 18: 848-852 [PMID: 22581031 DOI: 10.1007/s10156-012-0425-4]
- 25 Abadi AT, Taghvaei T, Mobarez AM, Carpenter BM, Merrell DS. Frequency of antibiotic resistance in Helicobacter pylori strains isolated from the northern population of Iran. *J Microbiol* 2011; 49: 987-993 [PMID: 22203563 DOI: 10.1007/s12275-011-1170-6]
- 26 **Shokrzadeh L**, Jafari F, Dabiri H, Baghaei K, Zojaji H, Alizadeh AH, Aslani MM, Zali MR. Antibiotic susceptibility profile of

Helicobacter pylori isolated from the dyspepsia patients in Tehran, Iran. *Saudi J Gastroenterol* 2011; **17**: 261-264 [PMID: 21727733 DOI: 10.4103/1319-3767.82581]

- 27 Farshad S, Alborzi A, Japoni A, Ranjbar R, Hosseini Asl K, Badiee P, Amin Shahidi M, Hosseini M. Antimicrobial susceptibility of Helicobacter pylori strains isolated from patients in Shiraz, Southern Iran. *World J Gastroenterol* 2010; 16: 5746-5751 [PMID: 21128326]
- 28 Talebi Bezmin Abadi A, Mobarez AM, Taghvaei T, Wolfram L. Antibiotic resistance of Helicobacter pylori in Mazandaran, North of Iran. *Helicobacter* 2010; 15: 505-509 [PMID: 21073606 DOI: 10.1111/j.1523-5378.2010.00795.x]
- 29 Guo S, He L, Zhang J, Zhou L, Ding Z, Zhang J, Yu F, Wang G, Zhou J, Guan D, Ji W, Xu X. [Antibiotic resistance of Helicobacter pylori in children and macrolide-resistant genotypes in Helicobacter pylori]. *Zhonghua Yi Xue Za Zhi* 2014; 94: 563-566 [PMID: 24762681]
- 30 Su P, Li Y, Li H, Zhang J, Lin L, Wang Q, Guo F, Ji Z, Mao J, Tang W, Shi Z, Shao W, Mao J, Zhu X, Zhang X, Tong Y, Tu H, Jiang M, Wang Z, Jin F, Yang N, Zhang J. Antibiotic resistance of Helicobacter pylori isolated in the Southeast Coastal Region of China. *Helicobacter* 2013; 18: 274-279 [PMID: 23418857 DOI: 10.1111/hel.1204]
- 31 Liu G, Xu X, He L, Ding Z, Gu Y, Zhang J, Zhou L. Primary antibiotic resistance of Helicobacter pylori isolated from Beijing children. *Helicobacter* 2011; 16: 356-362 [PMID: 21923681 DOI: 10.1111/j.1523-5378.2011.00856.x]
- 32 Gao W, Cheng H, Hu F, Li J, Wang L, Yang G, Xu L, Zheng X. The evolution of Helicobacter pylori antibiotics resistance over 10 years in Beijing, China. *Helicobacter* 2010; 15: 460-466 [PMID: 21083752 DOI: 10.1111/j.1523-5378.2010.00788.x]
- 33 Huang LP, Zhuang ML, Gu CP. [Antimicrobial resistance of 36 strains of Helicobacter pylori in adolescents]. *Zhongguo Dang Dai* Er Ke Za Zhi 2009; 11: 210-212 [PMID: 19292962]
- 34 Nishizawa T, Maekawa T, Watanabe N, Harada N, Hosoda Y, Yoshinaga M, Yoshio T, Ohta H, Inoue S, Toyokawa T, Yamashita H, Saito H, Kuwai T, Katayama S, Masuda E, Miyabayashi H, Kimura T, Nishizawa Y, Takahashi M, Suzuki H. Clarithromycin Versus Metronidazole as First-line Helicobacter pylori Eradication: A Multicenter, Prospective, Randomized Controlled Study in Japan. *J Clin Gastroenterol* 2015; 49: 468-471 [PMID: 24921211]
- 35 Morimoto N, Takeuchi H, Nishida Y, Morisawa M, Yoshikawa T, Morita T, Morimoto M, Sugimoto C, Matsumura Y, Sugiura T. Clinical Application of the DiversiLab Microbial Typing System Using Repetitive Sequence-Based PCR for Characterization of Helicobacter pylori in Japan. *J Clin Lab Anal* 2015; **29**: 250-253 [PMID: 24796534 DOI: 10.1002/jcla.21758]
- 36 Okamura T, Suga T, Nagaya T, Arakura N, Matsumoto T, Nakayama Y, Tanaka E. Antimicrobial resistance and characteristics of eradication therapy of Helicobacter pylori in Japan: a multigenerational comparison. *Helicobacter* 2014; 19: 214-220 [PMID: 24758533 DOI: 10.1111/hel.12124]
- 37 Murakami K, Furuta T, Ando T, Nakajima T, Inui Y, Oshima T, Tomita T, Mabe K, Sasaki M, Suganuma T, Nomura H, Satoh K, Hori S, Inoue S, Tomokane T, Kudo M, Inaba T, Take S, Ohkusa T, Yamamoto S, Mizuno S, Kamoshida T, Amagai K, Iwamoto J, Miwa J, Kodama M, Okimoto T, Kato M, Asaka M. Multicenter randomized controlled study to establish the standard third-line regimen for Helicobacter pylori eradication in Japan. *J Gastroenterol* 2013; **48**: 1128-1135 [PMID: 23307042 DOI: 10.1007/s00535-012-0731-8]
- 38 Yamade M, Sugimoto M, Uotani T, Nishino M, Kodaira C, Furuta T. Resistance of Helicobacter pylori to quinolones and clarithromycin assessed by genetic testing in Japan. J Gastroenterol Hepatol 2011; 26: 1457-1461 [PMID: 21679250 DOI: 10.1111/ j.1440-1746.2011.06815.x]
- 39 Kato S, Fujimura S. Primary antimicrobial resistance of Helicobacter pylori in children during the past 9 years. *Pediatr Int* 2010; 52: 187-190 [PMID: 19563459 DOI: 10.1111/j.1442-200X.2009.02915.x]
- 40 Yoon KH, Park SW, Lee SW, Kim BJ, Kim JG. Clarithromycin-

based standard triple therapy can still be effective for Helicobacter pylori eradication in some parts of the Korea. *J Korean Med Sci* 2014; **29**: 1240-1246 [PMID: 25246742 DOI: 10.3346/jkms.2014.2 9.9.1240]

- 41 An B, Moon BS, Kim H, Lim HC, Lee YC, Lee G, Kim SH, Park M, Kim JB. Antibiotic resistance in Helicobacter pylori strains and its effect on H. pylori eradication rates in a single center in Korea. *Ann Lab Med* 2013; 33: 415-419 [PMID: 24205490 DOI: 10.3343/ alm.2013.33.6.415]
- 42 Kim BJ, Kim JG. Substitutions in penicillin-binding protein 1 in amoxicillin-resistant Helicobacter pylori strains isolated from Korean patients. *Gut Liver* 2013; 7: 655-660 [PMID: 24312705 DOI: 10.5009/gnl.2013.7.6.655]
- 43 Chung JW, Lee GH, Jeong JY, Lee SM, Jung JH, Choi KD, Song HJ, Jung HY, Kim JH. Resistance of Helicobacter pylori strains to antibiotics in Korea with a focus on fluoroquinolone resistance. *J Gastroenterol Hepatol* 2012; 27: 493-497 [PMID: 21793912 DOI: 10.1111/j.1440-1746.2011.06874.x]
- 44 Alfizah H, Norazah A, Hamizah R, Ramelah M. Resistotype of Helicobacter pylori isolates: the impact on eradication outcome. J Med Microbiol 2014; 63: 703-709 [PMID: 24757218 DOI: 10.1099/ jmm.0.069781-0]
- 45 Teh X, Khosravi Y, Lee WC, Leow AH, Loke MF, Vadivelu J, Goh KL. Functional and molecular surveillance of Helicobacter pylori antibiotic resistance in Kuala Lumpur. *PLoS One* 2014; 9: e101481 [PMID: 25003707 DOI: 10.1371/journal.pone.0101481]
- 46 Goh KL, Navaratnam P. High Helicobacter pylori resistance to metronidazole but zero or low resistance to clarithromycin, levofloxacin, and other antibiotics in Malaysia. *Helicobacter* 2011; 16: 241-245 [PMID: 21585611 DOI: 10.1111/j.1523-5378.2011.008 41.x]
- 47 Ahmad N, Zakaria WR, Mohamed R. Analysis of antibiotic susceptibility patterns of Helicobacter pylori isolates from Malaysia. *Helicobacter* 2011; 16: 47-51 [PMID: 21241412 DOI: 10.1111/j.15 23-5378.2010.00816.x]
- 48 Ahmad N, Zakaria WR, Abdullah SA, Mohamed R. Characterization of clarithromycin resistance in Malaysian isolates of Helicobacter pylori. *World J Gastroenterol* 2009; 15: 3161-3165 [PMID: 19575497]
- 49 Rasheed F, Campbell BJ, Alfizah H, Varro A, Zahra R, Yamaoka Y, Pritchard DM. Analysis of clinical isolates of Helicobacter pylori in Pakistan reveals high degrees of pathogenicity and high frequencies of antibiotic resistance. *Helicobacter* 2014; **19**: 387-399 [PMID: 24827414 DOI: 10.1111/hel.12142]
- 50 Khan A, Farooqui A, Manzoor H, Akhtar SS, Quraishy MS, Kazmi SU. Antibiotic resistance and cagA gene correlation: a looming crisis of Helicobacter pylori. *World J Gastroenterol* 2012; 18: 2245-2252 [PMID: 22611319 DOI: 10.3748/wjg.v18.i18.2245]
- 51 Yakoob J, Abid S, Abbas Z, Jafri SN. Antibiotic susceptibility patterns of Helicobacter pylori and triple therapy in a highprevalence area. *Br J Biomed Sci* 2010; 67: 197-201 [PMID: 21294447]
- 52 Karabiber H, Selimoglu MA, Otlu B, Yildirim O, Ozer A. Virulence factors and antibiotic resistance in children with Helicobacter pylori gastritis. *J Pediatr Gastroenterol Nutr* 2014; 58: 608-612 [PMID: 24792628 DOI: 10.1097/MPG.0000000000273]
- 53 Cağdaş U, Otağ F, Tezcan S, Sezgin O, Aslan G, Emekdaş G. [Detection of Helicobacter pylori and antimicrobial resistance in gastric biopsy specimens]. *Mikrobiyol Bul* 2012; 46: 398-409 [PMID: 22951652]
- 54 Ozbey G, Bahcecioglu IH, Acik MN. Resistance Rates to Various Antimicrobial Agents of Helicobacter pylori Isolates in Eastern Turkey. *IJMCM* 2012; 2: 148-152
- 55 Bakir Ozbey S, Ozakin C, Keskin M. [Antibiotic resistance rates of Helicobacter pylori isolates and the comparison of E-test and fluorescent in situ hybridization methods for the detection of clarithromycin resistant strains]. *Mikrobiyol Bul* 2009; **43**: 227-234 [PMID: 19621607]
- 56 Safak B, Ciftei IH, Ozdemir M, Kiyildi N, Cetinkaya Z, Aktepe OC, Altindis M, Asik G. In vitro anti-Helicobacter pylori activity

of usnic acid. *Phytother Res* 2009; **23**: 955-957 [PMID: 19367654 DOI: 10.1002/ptr.2690]

- 57 Liang CM, Cheng JW, Kuo CM, Chang KC, Wu KL, Tai WC, Chiu KW, Chiou SS, Lin MT, Hu TH, Chuah SK. Levofloxacincontaining second-line anti-Helicobacter pylori eradication in Taiwanese real-world practice. *Biomed J* 2014; 37: 326-330 [PMID: 25163495 DOI: 10.4103/2319-4170.125650]
- 58 Chang WL, Sheu BS, Cheng HC, Yang YJ, Yang HB, Wu JJ. Resistance to metronidazole, clarithromycin and levofloxacin of Helicobacter pylori before and after clarithromycin-based therapy in Taiwan. J Gastroenterol Hepatol 2009; 24: 1230-1235 [PMID: 19476562 DOI: 10.1111/j.1440-1746.2009.05829.x]
- 59 Tanuma M, Rimbara E, Noguchi N, Boonyaritichaikij S, Kuwabara K, Fukunaga Y, Sasatsu M. Analysis of clarithromycin resistance and CagA status in Helicobacter pylori by use of feces from children in Thailand. *J Clin Microbiol* 2009; 47: 4144-4145 [PMID: 19794037 DOI: 10.1128/JCM.00786-09]
- 60 Alfaresi MS, Elkoush AA. Characterization of clarithromycin resistance in isolates of Helicobacter pylori from the UAE. *Indian J Gastroenterol* 2010; 29: 116-120 [PMID: 20658326 DOI: 10.1007/ s12664-010-0034-z]
- 61 Pandya HB, Agravat HH, Patel JS, Sodagar NR. Emerging antimicrobial resistance pattern of Helicobacter pylori in central Gujarat. *Indian J Med Microbiol* 2014; **32**: 408-413 [PMID: 25297026 DOI: 10.4103/0255-0857.142256]
- 62 Binh TT, Shiota S, Nguyen LT, Ho DD, Hoang HH, Ta L, Trinh DT, Fujioka T, Yamaoka Y. The incidence of primary antibiotic resistance of Helicobacter pylori in Vietnam. *J Clin Gastroenterol* 2013; 47: 233-238 [PMID: 23090037 DOI: 10.1097/ MCG.0b013e3182676e2b]
- 63 Picoli SU, Mazzoleni LE, Fernández H, De Bona LR, Neuhauss E, Longo L, Prolla JC. Resistance to amoxicillin, clarithromycin and ciprofloxacin of Helicobacter pylori isolated from Southern Brazil patients. *Rev Inst Med Trop Sao Paulo* 2014; 56: 197-200 [PMID: 24878996]
- 64 Ogata SK, Godoy AP, da Silva Patricio FR, Kawakami E. High Helicobacter pylori resistance to metronidazole and clarithromycin in Brazilian children and adolescents. J Pediatr Gastroenterol Nutr 2013; 56: 645-648 [PMID: 23403439 DOI: 10.1097/ MPG.0b013e31828b3669]
- 65 Eisig JN, Silva FM, Barbuti RC, Navarro-Rodriguez T, Moraes-Filho JP, Pedrazzoli Jr J. Helicobacter pylori antibiotic resistance in Brazil: clarithromycin is still a good option. *Arq Gastroenterol* 2011; 48: 261-264 [PMID: 22147131]
- 66 Figueroa M, Cortés A, Pazos Á, Bravo LE. [Antimicrobial susceptibility of Helicobacter pylori with chronic gastritis]. *Biomedica* 2012; 32: 32-42 [PMID: 23235785 DOI: 10.1590/S0120-41572012 000100005]
- 67 Llanes R, Soria C, Nagashima S, Kobayashi N, Gala A, Guzmán D, Feliciano O, Valdés L, Gutiérrez O, Fernández H, Llop A, Wada A. Phenotypic and genetic characterization of antimicrobial profiles of Helicobacter pylori strains in Cuba. *J Health Popul Nutr* 2010; 28: 124-129 [PMID: 20411674]
- 68 Mochizuki Tamayo H, Noriega Aldave AP. [Antimicrobial susceptibility of helicobacter pylori to levofloxacin determined in a miniwell format and disk diffusion tests using egg yolk agar]. *Rev Gastroenterol Peru* 2011; **31**: 224-229 [PMID: 22086316]
- 69 Torres-Debat ME, Pérez-Pérez G, Olivares A, Fernández L, Raisler K, González N, Stein S, Bazet MC, Alallón W, Cohen H. Antimicrobial susceptibility of Helicobacter pylori and mechanisms of clarithromycin resistance in strains isolated from patients in Uruguay. *Rev Esp Enferm Dig* 2009; 101: 757-762 [PMID: 20001152]
- 70 Ayala G, Galván-Portillo M, Chihu L, Fierros G, Sánchez A, Carrillo B, Román A, López-Carrillo L, Silva-Sánchez J. Resistance to antibiotics and characterization of Helicobacter pylori strains isolated from antrum and body from adults in Mexico. *Microb Drug Resist* 2011; 17: 149-155 [PMID: 21303219 DOI: 10.1089/ mdr.2010.0154]
- 71 Slinger R, Yan L, Chan F, Forward K, Cooper-Lesins G, Best L,



Haldane D, Veldhuyzen van Zanten S. Pyrosequencing assay to rapidly detect clarithromycin resistance mutations in Canadian Helicobacter pylori isolates. *Can J Gastroenterol* 2009; **23**: 609-612 [PMID: 19816623]

- 72 Tveit AH, Bruce MG, Bruden DL, Morris J, Reasonover A, Hurlburt DA, Hennessy TW, McMahon B. Alaska sentinel surveillance study of Helicobacter pylori isolates from Alaska Native persons from 2000 to 2008. J Clin Microbiol 2011; 49: 3638-3643 [PMID: 21813726 DOI: 10.1128/JCM.01067-11]
- 73 Seck A, Burucoa C, Dia D, Mbengue M, Onambele M, Raymond J, Breurec S. Primary antibiotic resistance and associated mechanisms in Helicobacter pylori isolates from Senegalese patients. *Ann Clin Microbiol Antimicrob* 2013; 12: 3 [PMID: 23298145 DOI: 10.1186/1476-0711-12-3]
- 74 Oyedeji KS, Smith SI, Coker AO, Arigbabu AO. Antibiotic susceptibility patterns in Helicobacter pylori strains from patients with upper gastrointestinal pathology in western Nigeria. *Br J Biomed Sci* 2009; 66: 10-13 [PMID: 19348120]
- 75 Secka O, Berg DE, Antonio M, Corrah T, Tapgun M, Walton R, Thomas V, Galano JJ, Sancho J, Adegbola RA, Thomas JE. Antimicrobial susceptibility and resistance patterns among Helicobacter pylori strains from The Gambia, West Africa. *Antimicrob Agents Chemother* 2013; 57: 1231-1237 [PMID: 23263004 DOI: 10.1128/AAC.00517-12]
- 76 Ben Mansour K, Burucoa C, Zribi M, Masmoudi A, Karoui S, Kallel L, Chouaib S, Matri S, Fekih M, Zarrouk S, Labbene M, Boubaker J, Cheikh I, Hriz MB, Siala N, Ayadi A, Filali A, Mami NB, Najjar T, Maherzi A, Sfar MT, Fendri C. Primary resistance to clarithromycin, metronidazole and amoxicillin of Helicobacter pylori isolated from Tunisian patients with peptic ulcers and gastritis: a prospective multicentre study. *Ann Clin Microbiol Antimicrob* 2010; **9**: 22 [PMID: 20707901 DOI: 10.1186/1476-0711-9-22]
- 77 Tanih NF, Okeleye BI, Naidoo N, Clarke AM, Mkwetshana N, Green E, Ndip LM, Ndip RN. Marked susceptibility of South African Helicobacter pylori strains to ciprofloxacin and amoxicillin: clinical implications. *S Afr Med J* 2010; 100: 49-52 [PMID: 20429489]
- 78 Wüppenhorst N, Draeger S, Stüger HP, Hobmaier B, Vorreiter J, Kist M, Glocker EO. Prospective multicentre study on antimicrobial resistance of Helicobacter pylori in Germany. *J Antimicrob Chemother* 2014; 69: 3127-3133 [PMID: 24997315 DOI: 10.1093/ jac/dku243]
- 79 Wueppenhorst N, Stueger HP, Kist M, Glocker EO. High secondary resistance to quinolones in German Helicobacter pylori clinical isolates. *J Antimicrob Chemother* 2013; 68: 1562-1566 [PMID: 23463210 DOI: 10.1093/jac/dkt061]
- 80 Selgrad M, Meissle J, Bornschein J, Kandulski A, Langner C, Varbanova M, Wex T, Tammer I, Schlüter D, Malfertheiner P. Antibiotic susceptibility of Helicobacter pylori in central Germany and its relationship with the number of eradication therapies. *Eur J Gastroenterol Hepatol* 2013; 25: 1257-1260 [PMID: 23863261 DOI: 10.1097/MEG.0b013e3283643491]
- 81 Saracino IM, Zullo A, Holton J, Castelli V, Fiorini G, Zaccaro C, Ridola L, Ricci C, Gatta L, Vaira D. High prevalence of primary antibiotic resistance in Helicobacter pylori isolates in Italy. J Gastrointestin Liver Dis 2012; 21: 363-365 [PMID: 23256118]
- 82 De Francesco V, Giorgio F, Ierardi E, Zotti M, Neri M, Milano A, Varasano V, Luzza F, Suraci E, Marmo R, Marone A, Manta R, Mirante VG, de Matthaeis M, Pedroni A, Manes G, Pallotta S, Usai P, Liggi M, Gatto G, Peri V, Sacco R, Bresci G, Monica F, Hassan C, Zullo A. Primary clarithromycin resistance in Helicobacter pylori: the Multicentric Italian Clarithromycin Resistance Observational (MICRO) study. *J Gastrointestin Liver Dis* 2011; 20: 235-239 [PMID: 21961089]
- 83 Chisholm SA, Owen RJ. Frequency and molecular characteristics of ciprofloxacin- and rifampicin-resistant Helicobacter pylori from gastric infections in the UK. *J Med Microbiol* 2009; 58: 1322-1328 [PMID: 19589906 DOI: 10.1099/jmm.0.011270-0]
- 84 Molina-Infante J, Romano M, Fernandez-Bermejo M, Federico

A, Gravina AG, Pozzati L, Garcia-Abadia E, Vinagre-Rodriguez G, Martinez-Alcala C, Hernandez-Alonso M, Miranda A, Iovene MR, Pazos-Pacheco C, Gisbert JP. Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance. *Gastroenterology* 2013; **145**: 121-128.e1 [PMID: 23562754 DOI: 10.1053/j.gastro.2013.03.050]

- 85 Cuadrado-Lavín A, Salcines-Caviedes JR, Carrascosa MF, Mellado P, Monteagudo I, Llorca J, Cobo M, Campos MR, Ayestarán B, Fernández-Pousa A, González-Colominas E. Antimicrobial susceptibility of Helicobacter pylori to six antibiotics currently used in Spain. *J Antimicrob Chemother* 2012; 67: 170-173 [PMID: 21965436 DOI: 10.1093/jac/dkr410]
- 86 Agudo S, Pérez-Pérez G, Alarcón T, López-Brea M. High prevalence of clarithromycin-resistant Helicobacter pylori strains and risk factors associated with resistance in Madrid, Spain. J Clin Microbiol 2010; 48: 3703-3707 [PMID: 20668128 DOI: 10.1128/ JCM.00144-10]
- 87 Agudo S, Alarcón T, Cibrelus L, Urruzuno P, Martínez MJ, López-Brea M. [High percentage of clarithromycin and metronidazole resistance in Helicobacter pylori clinical isolates obtained from Spanish children]. *Rev Esp Quimioter* 2009; 22: 88-92 [PMID: 19544100]
- 88 Larsen AL, Ragnhildstveit E, Moayeri B, Eliassen L, Melby KK. Resistance rates of metronidazole and other antibacterials in Helicobacter pylori from previously untreated patients in Norway. *APMIS* 2013; **121**: 353-358 [PMID: 23083455 DOI: 10.1111/ apm.12009]
- 89 Kostamo P, Veijola L, Oksanen A, Sarna S, Rautelin H. Recent trends in primary antimicrobial resistance of Helicobacter pylori in Finland. *Int J Antimicrob Agents* 2011; 37: 22-25 [PMID: 21084175 DOI: 10.1016/j.ijantimicag.2010.09.013]
- 90 Boyanova L, Ilieva J, Gergova G, Evstatiev I, Nikolov R, Mitov I. Living in Sofia is associated with a risk for antibiotic resistance in Helicobacter pylori: a Bulgarian study. *Folia Microbiol* (Praha) 2013; 58: 587-591 [PMID: 23580173 DOI: 10.1007/s12223-013-0251-9]
- 91 Boyanova L, Ilieva J, Gergova G, Davidkov L, Spassova Z, Kamburov V, Katsarov N, Mitov I. Numerous risk factors for Helicobacter pylori antibiotic resistance revealed by extended anamnesis: a Bulgarian study. *J Med Microbiol* 2012; 61: 85-93 [PMID: 21873378 DOI: 10.1099/jmm.0.035568-0]
- 92 Boyanova L. Prevalence of multidrug-resistant Helicobacter pylori in Bulgaria. *J Med Microbiol* 2009; 58: 930-935 [PMID: 19502370 DOI: 10.1099/jmm.0.009993-0]
- 93 Hojsak I, Kos T, Dumančić J, Mišak Z, Jadrešin O, Jaklin Kekez A, Lukić Grlić A, Kolaček S. Antibiotic resistance of Helicobacter pylori in pediatric patients -- 10 years' experience. *Eur J Pediatr* 2012; 171: 1325-1330 [PMID: 22430353 DOI: 10.1007/s00431-01 2-1722-8]
- 94 Karczewska E, Klesiewicz K, Wojtas-Bonior I, Skiba I, Sito E, Czajecki K, Zwolińska-Wcisło M, Budak A. Levofloxacin resistance of Helicobacter pylori strains isolated from patients in southern Poland, between 2006-2012. *Acta Pol Pharm* 2014; 71: 477-483 [PMID: 25265828]
- 95 Gościniak G, Biernat M, Grabińska J, Bińkowska A, Poniewierka E, Iwańczak B. The antimicrobial susceptibility of Helicobacter pylori strains isolated from children and adults with primary infection in the Lower Silesia Region, Poland. *Pol J Microbiol* 2014; **63**: 57-61 [PMID: 25033663]
- 96 Karczewska E, Klesiewicz K, Skiba I, Wojtas-Bonior I, Sito E, Czajecki K, Zwolińska-Wcisło M, Budak A. Variability in Prevalence of Helicobacter pylori Strains Resistant to Clarithromycin and Levofloxacin in Southern Poland. *Gastroenterol Res Pract* 2012; 2012: 418010 [PMID: 22693490 DOI: 10.1155/2012/418010]
- 97 Karczewska E, Wojtas-Bonior I, Sito E, Zwolińska-Wcisło M, Budak A. Primary and secondary clarithromycin, metronidazole, amoxicillin and levofloxacin resistance to Helicobacter pylori in southern Poland. *Pharmacol Rep* 2011; 63: 799-807 [PMID: 21857091]

- 98 Almeida N, Romãozinho JM, Donato MM, Luxo C, Cardoso O, Cipriano MA, Marinho C, Fernandes A, Calhau C, Sofia C. Helicobacter pylori antimicrobial resistance rates in the central region of Portugal. *Clin Microbiol Infect* 2014; **20**: 1127-1133 [PMID: 24890952 DOI: 10.1111/1469-0691.12701]
- 99 Oleastro M, Cabral J, Ramalho PM, Lemos PS, Paixão E, Benoliel J, Santos A, Lopes AI. Primary antibiotic resistance of Helicobacter pylori strains isolated from Portuguese children: a prospective multicentre study over a 10 year period. J Antimicrob Chemother 2011; 66: 2308-2311 [PMID: 21764826 DOI: 10.1093/jac/dkr293]
- 100 Vekens K, Vandebosch S, De Bel A, Urbain D, Mana F. Primary antimicrobial resistance of Helicobacter pylori in Belgium. *Acta Clin Belg* 2013; 68: 183-187 [PMID: 24156217]
- 101 Miendje Deyi VY, Bontems P, Vanderpas J, De Koster E, Ntounda R, Van den Borre C, Cadranel S, Burette A. Multicenter survey of routine determinations of resistance of Helicobacter pylori to antimicrobials over the last 20 years (1990 to 2009) in Belgium. *J Clin Microbiol* 2011; **49**: 2200-2209 [PMID: 21450969 DOI: 10.1128/JCM.02642-10]
- 102 de Boer EM, Schneeberger PM, de Boer WA. [Antibiotic resistance of Helicobacter pylori: prevalence in one region in the southern Netherlands and implications for treatment]. *Ned Tijdschr Geneeskd* 2014; 158: A7501 [PMID: 25159698]
- 103 Loffeld RJ, Werdmuller BF. Changes in Antibiotic Susceptibility of Helicobacter pylori in the Course of Eight Years in the Zaanstreek Region in The Netherlands. *Gastroenterol Res Pract* 2013; 2013: 625937 [PMID: 23573077 DOI: 10.1155/2013/625937]
- 104 O'Connor A, Taneike I, Nami A, Fitzgerald N, Ryan B, Breslin N, O'Connor H, McNamara D, Murphy P, O'Morain C. Helicobacter pylori resistance rates for levofloxacin, tetracycline and rifabutin among Irish isolates at a reference centre. *Ir J Med Sci* 2013; 182: 693-695 [PMID: 23625165 DOI: 10.1007/s11845-013-0957-3]
- 105 O'connor A, Taneike I, Nami A, Fitzgerald N, Murphy P, Ryan B, O'connor H, Qasim A, Breslin N, O'moráin C. Helicobacter pylori resistance to metronidazole and clarithromycin in Ireland. *Eur J Gastroenterol Hepatol* 2010; 22: 1123-1127 [PMID: 20354442 DOI: 10.1097/MEG.0b013e328338e43d]
- 106 Montes M, Villalon FN, Eizaguirre FJ, Delgado M, Muñoz-Seca

IM, Fernández-Reyes M, Pérez-Trallero E. Helicobacter pylori Infection in Children. Antimicrobial Resistance and Treatment Response. *Helicobacter* 2015; **20**: 169-175 [PMID: 25382231 DOI: 10.1111/hel.12187]

- 107 Mégraud F. Current recommendations for Helicobacter pylori therapies in a world of evolving resistance. *Gut Microbes* 2013; 4: 541-548 [PMID: 23929066 DOI: 10.4161/gmic.25930]
- 108 Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, Andersen LP, Goossens H, Glupczynski Y. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. *Gut* 2013; 62: 34-42 [PMID: 22580412 DOI: 10.1136/gutjnl-2012-302254]
- 109 Mégraud F, Lamouliatte H. Review article: the treatment of refractory Helicobacter pylori infection. *Aliment Pharmacol Ther* 2003; 17: 1333-1343 [PMID: 12786627]
- 110 Dammann HG, Fölsch UR, Hahn EG, von Kleist DH, Klör HU, Kirchner T, Strobel S, Kist M. Eradication of H. pylori with pantoprazole, clarithromycin, and metronidazole in duodenal ulcer patients: a head-to-head comparison between two regimens of different duration. *Helicobacter* 2000; 5: 41-51 [PMID: 10672051]
- 111 Frenck RW, Clemens J. Helicobacter in the developing world. Microbes Infect 2003; 5: 705-713 [PMID: 12814771]
- 112 Ecclissato C, Marchioretto MA, Mendonça S, Godoy AP, Guersoni RA, Deguer M, Piovesan H, Ferraz JG, Pedrazzoli J. Increased primary resistance to recommended antibiotics negatively affects Helicobacter pylori eradication. *Helicobacter* 2002; 7: 53-59 [PMID: 11886474]
- 113 Realdi G, Dore MP, Piana A, Atzei A, Carta M, Cugia L, Manca A, Are BM, Massarelli G, Mura I, Maida A, Graham DY. Pretreatment antibiotic resistance in Helicobacter pylori infection: results of three randomized controlled studies. *Helicobacter* 1999; 4: 106-112 [PMID: 10382124]
- 114 Gisbert JP, Castro-Fernandez M, Perez-Aisa A, Cosme A, Molina-Infante J, Rodrigo L, Modolell I, Cabriada JL, Gisbert JL, Lamas E, Marcos E, Calvet X. Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures. *Aliment Pharmacol Ther* 2012; 35: 941-947 [PMID: 22372560 DOI: 10.1111/j.1365-2036.2012.05053.x]
 - P- Reviewer: Franceschi F, Gao ZJ, Safaei HG, Yuan Y S- Editor: Ji FF L- Editor: A E- Editor: Jiao XK







Published by Baishideng Publishing Group Inc

8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com

